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Abstract 
 
In human, loss of Acid Sphingomeylinase (ASM/SMPD1) causes Niemann-Pick Disease, type A. 
ASM hydrolyzes sphingomyelins to produce ceramides but protein targets of ASM remain largely 
unclear. Our mass-spectrometry-based proteomic analyses have identified >100 proteins associated 
with the ASM-dependent, detergent-resistant membrane microdomains (lipid rafts), with >60% of 
these proteins being palmitoylated, including SNAP23, Src-family kinases Yes and Lyn, and Ras 
and Rab family small GTPases. Inactivation of ASM abolished the presence of these proteins in 
the plasma membrane, with many of them trapped in the Golgi. While palmitoylation inhibitors 
and palmitoylation mutants phenocopied the effects of ASM inactivation, we demonstrated that 
ASM is required for the transport of palmitoylated proteins, such as SNAP23 and Lyn, from the 
Golgi to the plasma membrane without affecting palmitoylation directly. Importantly, ASM 
delivered extracellularly can regulate the trafficking of SNAP23 from the Golgi to the plasma 
membrane. Our studies suggest that ASM, acting at the plasma membrane to produce ceramides, 
regulates the localization and trafficking of the palmitoylated proteins.  
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Introduction 
The plasma membrane is a lipid bilayer composed primarily of phospholipids, as well as 
sphingomyelins, cholesterol, glycol-sphingolipids and other less abundant lipid molecules such as 
ceramides (Holthuis and Menon, 2014). Sphingomyelins comprise about 10-20% total lipids and 
are asymmetrically localized in the outer leaflet of the lipid bilayer of the plasma membrane 
(Holthuis and Menon, 2014). Sphingomyelins can also interact with cholesterol through their acyl 
tails. The tightly packing of sphingomyelins and cholesterol can form an ordered lipid 
microdomain, the lipid raft (Simons and Ikonen, 1997). Increasing evidence suggests that lipid 
rafts can serve as signaling platforms to facilitate protein-protein interactions, as demonstrated for 
the activation of T cell receptor (Lingwood and Simons, 2010; Rajendran and Simons, 2005). 
Sphingomyelins can be converted to ceramides through the action of sphingomyelinases. 
Ceramides, composed of a sphingosine and a fatty acid, are much more hydrophobic than 
sphingomyelin. Ceramides can self-associate to form unique lipid microdomains in artificial 
membrane or in the plasma membrane of erythrocytes (Holopainen et al., 1998; Lopez-Montero et 
al., 2010; van Blitterswijk et al., 2003).  
 
ASM (Acid Sphingomeylinase) catalyzes the hydrolysis of sphingomyelins to produce ceramides 
and phosphocholine (Jenkins et al., 2009; Schuchman, 2007). In humans, loss-of-function 
mutations in the ASM gene (also called SMPD1) cause the familial Niemann-Pick Disease, type A, 
with severe neurological deterioration and lysosomal accumulation of excessive sphingomyelins in 
brain, liver, spleen and lung cells, leading to the death of affected individuals at 1 or 2 years of age 
(Schuchman, 2007). Biochemically, ASM acts as an sphingomyelinase that catalyzes the 
hydrolysis of sphingomyelin to produce ceremides and phosphorylcholine. The precursors of 
sphingomylin are first synthesized from ceramides in the endoplasmic reticulum (ER), transported 
to the Golgi Apparatus, and converted to sphingomyelin by sphingomyelin synthase 1 and 2 
(SMS1 and 2) (Huitema et al., 2004). Sphingomylin is then transported to the outer leaflet of the 
plasma lipid bilayer membrane. ASM, containing a saposin-like domain that is likely involved in 
binding to sphingomyelins (Jenkins et al., 2009), is also exported, likely from lysosomes, to the 
outer leaflet of plasma membrane to hydrolyze sphingomyelin into ceremides, which can form the 
ceremide-enriched lipid rafts in response to stress stimuli (Cremesti et al., 2001; Grassme et al., 
2003; Lopez-Montero et al., 2010; Tam et al., 2010; van Blitterswijk et al., 2003). Under normal 
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conditions, the ratio of ceramides to sphingomeylins on the plasma membrane is usually low (1-
5%) (Lopez-Montero et al., 2010; van Blitterswijk et al., 2003). However, in the ASM knockout 
mice, many pathological defects of Niemann-Pick Type A diseases were reproduced, including the 
extensive accumulation of sphingomyelin in liver, spleen, lung and brain cells (Horinouchi et al., 
1995; Otterbach and Stoffel, 1995). These genetic studies demonstrate that ASM is a dynamic and 
critical regulator of sphingomyelin homeostasis in the plasma membrane. However, the 
physiological function of ASM and the critical protein targets regulated by ASM remain unclear. 
 
Palmitoylation is a post-translational modification of proteins that involves the covalent attachment 
of saturated fatty acids, predominantly the C16:0 palmitate, to cysteine residues via a thioester 
linkage (Charollais and Van Der Goot, 2009; Resh, 2013; Salaun et al., 2010). Palmitoylation 
tethers the otherwise cytosolic proteins to the inner leaflets of the plasma membrane to facilitate 
the lateral diffusion of proteins in the plasma membrane and to promote protein-protein interaction, 
and is critical for signal transduction, synaptic function, membrane trafficking, and vesicle fusion 
(Bijlmakers and Marsh, 2003; Smotrys and Linder, 2004). Many proteins, including the Src family 
tyrosine kinases such as Yes and Lyn, membrane trafficking proteins such as SNARE (soluble 
NSF attachment protein receptor) proteins, Ras family of small GTPases, receptors and channel 
proteins, are modified by palmitate to regulate their membrane-associated activities. Although 
palmitoylated proteins have been reported to be associated with lipid rafts in a manner requires 
cholesterol participation (Chakrabandhu et al., 2007; Levental et al., 2010; Melkonian et al., 1999), 
the roles of ceramides in such association remain undetermined.  
 
We have recently conducted a functional genome-wide screen in C. elegans and identified the 
worm homolog of ASM, asm-3, as a positive and novel regulator of the evolutionarily conserved 
IGF-1 receptor (IGF-1R)-like signaling pathway (Kim and Sun, 2007; Kim and Sun, 2012). Our 
recent studies in mammalian cells have shown that human ASM indeed functions to regulate the 
receptor tyrosine kinase signaling pathways such as the Met tyrosine kinase signaling (Zhu et al., 
2016). In this report, we have used semi-quantitative proteomic approaches to identify proteins 
associated with lipid rafts that are regulated by ASM in human cells. Our studies have revealed 
novel function of ASM in regulation of intracellular protein localization and trafficking. 
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Results 
 
Using a biochemical procedure to fractionate ASM-regulated membrane-associated proteins 
 
It has been shown that activation of CD95 death receptor in lymphoid cells is accompanied by the 
CD95 receptor localization into the ceramide-rich lipid rafts, and such localization is ASM-
dependent, leading to CD95 receptor oligomerization, signaling and apoptosis (Cremesti et al., 
2001; Lopez-Montero et al., 2010; van Blitterswijk et al., 2003). However, our recent genetic 
studies have shown that the C. elegans homolog of ASM is a positive regulator of the conserved 
IGF-1R-like signaling pathway in vivo (Kim and Sun, 2007; Kim and Sun, 2012). We wondered if 
ASM might regulate the localization of proteins in the ceramide-rich lipid rafts, and these proteins 
might be positively involved in receptor tyrosine kinase signaling under physiological conditions. 
To identify such proteins, we took a biochemical approach to isolate lipid rafts and analyze the 
associated proteins by mass-spectrometry. By comparing the lipid raft proteomes identified in cells 
with ASM or without ASM, we aim to identify the lipid raft-associated proteins that are regulated 
by ASM.  
 
The sphingomyelin-enriched lipid microdomains are known to be relatively resistant to nonionic 
detergents, such as Triton X-100, and can be isolated as “the detergent-resistant membrane (DRM) 
fractions”, which can be separated from the detergent-soluble fractions using a sucrose gradient 
and ultracentrifugation (Harder et al., 1998; Schuck et al., 2003). Since lipid microdomains are 
heterogeneous with varying lipid composition and protein content, their resistances to various 
detergents are known to be different (Giurisato et al., 2003; Radeva and Sharom, 2004; Schuck et 
al., 2003). The detergent Brij has been shown to preserve the lipid raft localization of 
transmembrane receptors (e.g., T cell receptor) better than Triton X-100 (Giurisato et al., 2003; 
Montixi et al., 1998; Roper et al., 2000). Human IGF-1R can also be fractionated in the detergent 
Brij-resistant membrane (DRM) fractions (Remacle-Bonnet et al., 2005). Since our genetic studies 
have established that the worm homolog of ASM regulates the IGF-1R-like signaling pathway in 
C. elegans (Kim and Sun, 2012), it is likely that human IGF-1R is also regulated by ASM. Indeed, 
in human glioblastoma U373-MG cells, which are highly sensitive to ASM inhibition (Zhu et al., 
2016), we found there is a small fraction of IGF-1R localized in the Brij-resistant membrane 
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(DRM) fractions (fraction #1-4). However, most of the IGF-1R protein was localized in the Brij-
soluble fractions (fractions #13-16) (Fig. 1A and 1B). We also found that the detergent Brij58, 
rather than Triton X-100, was more efficient in preserving the lipid raft localization of IGF-1R 
(data not shown). In cells treated with desipramine, the localization of IGF-1R in the DRM 
fractions was reduced (Fig. 1B). Desipramine is a tricyclic amine anti-depression drug that acts as 
a functional inhibitor of ASM, and the drug blocks the interaction of ASM with membrane inside 
the lysosomes and causes ASM degradation (Albouz et al., 1981; Jaffrezou et al., 1995; Jenkins et 
al., 2011; Zhu et al., 2016). Indeed, the ASM activity was potently suppressed in cells treated with 
desipramine, confirmed by assaying the ASM activities using 14C-sphingomyelin as a substrate 
(Fig. 1E).  
 
As control, we have found that Yes, a member of the src-family kinases known to be associated 
with lipid rafts (Radeva and Sharom, 2004; Schuck et al., 2003), is also localized in the Brij-DRM 
fractions (Fig. 1B). As the DRM fractions only contain 1% of total proteins (based on 
quantification of protein concentrations using the Bradford assay), our studies revealed that Yes is 
enriched in the DRM fractions. In cells treated with desipramine, there was a significantly reduced 
level of the Yes protein in the DRM fractions, while the protein level of Yes in the soluble 
fractions was slightly increased (Fig. 1B). In addition, we also found that a fraction of flotillin, a 
known lipid raft protein, also associated with the Brij58-resistant lipid membrane fractions and this 
membrane-associated fraction is also reduced after desipramine treatment (Fig. 1B). To confirm 
these results, we also used two different ASM siRNAs to verify the reduced levels of Yes protein 
in the DRM fractions in the ASM-inactivated cells (Fig. 1C and 1G). The Yes protein distribution 
in the pooled DRM fractions and pooled soluble fraction were also examined (Fig. 1G). In these 
experiments, the efficiency of ASM siRNAs on ASM gene silencing was confirmed by assaying 
the ASM activities using 14C-sphingomyelin as a substrate (Fig. 1E). The effects on ASM protein 
levels by ASM siRNAs were also confirmed by immunoprecipitation/Western blot analysis, since 
ASM protein was too low in abundance to be detected by straight Western blot analysis  (Fig. 1F).  
 
As cholesterol is reported to be involved in the formation of sphingomyelin-enriched lipid rafts, we 
also tested the effects of cholesterol depletion on membrane proteins. Methyl-β-cyclodextrin 
(MβCD) is a specific chemical that removes cholesterol from cultured cells. Previous reports 
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showed that depletion of cellular cholesterol by MβCD is accompanied with the loss of 
sphingomyelin-enriched membrane rafts (Klein et al., 1995). We found that MβCD treatment also 
caused the reduction of Yes from the DRM fractions (Fig. 1D), suggesting that Yes is associated 
with lipid membranes that are sensitive to ASM and cholesterol depletion.  
 
Mass-spectrometry analysis of ASM-dependent membrane-associated proteins 
Having established a biochemical fractionation method to fractionate ASM-sensitive DRM 
proteins, we took a proteomic approach to interrogate the DRM-associated proteins that are 
potentially regulated by ASM (Fig. 2A). Briefly, U373-MG cells, treated with control or ASM 
specific siRNAs, were lysed in the Brij58-containing buffer and fractionated by ultracentrifugation 
on a sucrose gradient. The (DRM) fractions (fractions #1 to #4) were pooled, resolved on SDS 
protein gel, followed by protein identification using an ESI-LTQ-Orbitrap XL mass-spectrometer 
(Thermo Electron). Proteomic profiling data were first analyzed by QualBrowser in Xcalibur and 
Proteome Discoverer and then by the Scaffold software to identify proteins with unique peptides 
(described in details in the Materials and Methods). The obtained data were then subjected to the 
label-free spectrum counting analysis, which has been used successfully to obtain a semi-
quantitative difference of protein abundance in two sets of the samples (Liu et al., 2004; Old et al., 
2005). Among 868 total protein hits analyzed, we have identified 108 DRM-associated proteins 
that show a greater than 2-fold reduction in the cells treated with ASM siRNAs (siASM), as 
compared with control cells treated with a non-specific luciferase siRNA (siLuc). These 108 
proteins consituted a high confidence group, each identified by at least two unique peptides, in the 
ASM-sensitive DRM-associated proteome (Suppl Table 1). The next group are 64 proteins, each 
identified by at least one unique peptide, that show a change of abundance of >1.8-fold, and these 
64 proteins constitutes the low confidence group (Suppl Table 1). However, not all proteins 
identified have a reduced DRM association when ASM is knockdown. In fact, there are 116 of 
proteins that show a greater than 2-fold increase with the DRM association when ASM is 
inactivated, including a few members in the integrin family (Suppl Table 2). These observations 
suggest that there present a set of proteins which association with DRM requires the function of 
ASM.  
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 Enrichment of palmitoylated proteins in the ASM sensitive membrane fractions 
When examining the list of proteins obtained by mass-spectrometry analyses (Suppl Table 1), we 
noticed that the majority of the identified DRM proteins that are senstive to the loss of ASM are 
peripherally membrane-associated proteins, whereas transmembrane proteins represent a relatively 
small group. This could be due to a poor recovery of the transmembrane proteins by the isolation 
procedure or due to the low abundance of the transmembrane proteins present in the DRM 
fractions. We focused on characterizing the peripherally membrane-associated proteins to 
investigate how these proteins might be associated with the ceramide-rich lipid rafts, as 
inactivation of ASM should reduce the levels of ceramides in the membrane. We wondered 
whether these proteins contain any common structural elements that help confer their membrane 
lipid association properties.  
 
During these mass-spectrometry-based proteomic analyses, we again recovered Yes as one of the 
ASM-sensitive DRM proteins (Fig. 2B and 2D). Yes is known to be tethered to the cytosolic face 
(the inner leaflet) of plasma membrane by palmitoylation (Resh, 1994; Sandilands et al., 2007). 
Since palmitoylation is the most common acylation event in eukaryotes that allows otherwise 
cytosolic proteins to be attached to the plasma membrane, we wondered if our ASM-sensitive 
proteome has a selective enrichment of proteins that are palmitoylated. We therefore closely 
examined whether there are additional palmitoylated proteins in our top list of the protein hits 
through database search of reported literature and also by cross-referencing the protein 
palmitoylation status in a palmitoyl-proteome database, the SwissPalm (Blanc et al., 2015). Indeed, 
among 108 proteins in our high-confidence group of the ASM-sensitive proteome, we have found 
that 60% of these proteins (65 out of 108 proteins) are known to be palmitoylated (Suppl Table 3), 
according to the previous studies by palmitoyl-proteomics analyses and other studies (Kang et al., 
2008; Rocks et al., 2010; Serwa et al., 2015). These 65 proteins can be categoried into cell surface 
receptors (14%), SFKs and Ras-family GTPases involved in cell signaling (13%), proteins 
participated in vesicular trafficking (31%), cytoskeleton reorganization (6%), scaffold proteins 
(11%), metabolism (13%), and other functions (12%) (Fig. 2C). Some examples of the 
palmitoylated proteins discovered in our ASM-sensitive DRM proteome are listed in Fig. 2B. 
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To verify the results from the mass-spectrometry-based proteomic analyses, we have examined 
several representative proteins by independent Western blot analysis. Our analysis revealed that 
similar to Yes, the levels of SNAP23 (the synaptosome-associated protein of 23 kDa), G(i)2 
(GNAI2, heterotrimeric G protein subunit) and Rab-family of GTPases Rab7, were reduced in the 
DRM fractions after cells were treated with ASM siRNAs (Fig. 2D). The membrane association of 
these proteins was also sensitive to ASM inhibitor desipramine (Fig. 2D). These studies indicate 
that our semi-quantitative mass-spectrometry analysis provides an effective way to identify the 
ASM-sensitive, DRM-associated proteins.  
 
The ASM-sensitive and DRM-localized proteins are palmitoylated proteins 
Our proteomic approach has identified proteins such as SNAP23, Yes and G(i)2 that were 
previously reported to be palmitoylated in other cells under various conditions. However, since 
palmitoylation is a dynamic post-translational process, we would like to ensure that these proteins 
are palmitoylated under our culture conditions in U373-MG cells. We therefore have used the 
Acyl-Biotinyl Exchange (ABE) assay to examine the palmitoylation status of various proteins we 
have identified (Fig. 2B and 2E). In the ABE assay (Kang et al., 2008; Roth et al., 2006), 
sequential chemical modifications were used to selectively labeling the palmitoylated proteins by 
biotin-HPDP, a sulfhydryl-reactive biotinylation reagent. The biotin-HPDP labeled proteins 
(palmitoylated proteins) can be pulled down by the streptavidin-agarose resins. Using this specific 
assay, we found that Yes, Lyn, Fyn, Ras, G(i)2, CD59, SNAP23, Rab7, and Rab14, which were 
identified in our ASM-sensitive, DRM proteome (Fig. 2B), were all palmitoylated proteins in 
U373-MG cells (Fig. 2E). Therefore, our proteome analysis selectively identified a large number 
of endogenous palmitoylated proteins that are enriched in ASM-regulated, DRM fractions in 
U373-MG cells.  
 
Loss of ASM diminishes the plasma membrane distribution of palmitoylated proteins 
Recent studies show that the Golgi apparatus is a major organelle to carry out the palmitoylation of 
proteins, e.g. H-Ras and Fyn, which undergo dynamic cycling between the Golgi and plasma 
membrane (Rocks et al., 2010; Rocks et al., 2005). These proteins are found to be palmitoylated on 
the Golgi, trafficked to the plasma membrane, and then rapidly depalmitoylated and returned to the 
Golgi, with a cycling time of about 20-30 minutes. We wondered whether ASM is involved in the 
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regulation of the rapid subcellular cycling of the palmitoylated proteins. We therefore examined 
the cellular localization of a group of palmitoylated proteins, including SNAP23, Yes, and G(i)2, 
by immunostaining. Our examination revealed that these endogenous proteins all showed a 
prominent localization in the plasma membrane in the control U373-MG cells (Fig. 3A and 3B, 
indicated by arrows). However, we found that knockdown of ASM by two independent siRNAs or 
treatment with desipramine, each greatly abolished the plasma membrane localization of these 
proteins (Fig. 3A and 3B). Our quantification of these analyses indicated that inactivation of ASM 
greatly diminished the plasma membrane distribution of these proteins (Fig. 3C and 3D). We also 
further examined the effects of ASM inactivation on other palmitoylated proteins such as Lyn and 
CD59. Our studies revealed that while both Lyn and CD59 are present on plasma membrane in 
control cells, siRNA-mediated knockdown of ASM led to the disappearance of these proteins from 
the plasma membrane (Fig. 3E). Our cell-based distribution studies, together with our mass 
spectrometry-based proteomic profiling, indicate that the palmitoylated proteins are enriched in 
ASM-sensitive DRM fractions and that ASM is required for the localization of these palmitoylated 
proteins to the plasma membrane.  
 
ASM deficiency causes the accumulation of SNAP23 in the TGN 
We have noticed that while loss of ASM causes the disappearance of these proteins on the plasma 
membrane, some proteins, such as SNAP23, started to accumulate in the intracellular perinuclear 
region (Fig. 3A and 3B). SNAP23 is a SNARE protein that is ubiquitously expressed in a variety 
of cells and is involved in a wide array of diverse vesicle membrane-membrane fusion events 
including exocytosis from mast cells, insulin-dependent release of GLUT4 from adipocytes, and 
neuronal postsynaptic glutamate receptor trafficking (Prescott et al., 2009). SNAP23 contains a 
centrally localized five cysteine residues that are shown to be linked to palmitoyl chains (Salaun et 
al., 2005) and our studies showed that SNAP23 is indeed palmitoylated in U373-MG cells (Fig. 
2E). To determine in which cellular compartment that SNAP23 may be trapped by the ASM 
deficiency in U373-MG cells, we conducted co-immunostaining experiments. Our examination 
revealed that siRNA-mediated knockdown of ASM caused the accumulation of SNAP23 in the 
TGN region, colocalized with the TGN marker TGN46, but not with the cis-Golgi marker GM130 
(Fig. 4A and 4B). We also examined the possibility that ASM inactivation may block the newly 
synthesized SNAP23 to be trafficked to the plasma membrane through the TGN (Fig. 4C). 
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However, treatment of cells with protein synthesis inhibitor, cycloheximide, did not block the 
presence of SNAP23 on the plasma membrane (Fig. 4C), suggesting SNAP23 is being recycled 
through the TGN to appear onto the plasma membrane. Our results indicate that ASM inactivation 
caused a failure of transport of SNAP23 out of the TGN.  
 
Inhibition of palmitoylation prevents the plasma membrane localization of SNAP23 
Since our studies indicate that ASM is required for the distribution of palmitoylated proteins such 
as SNAP23 to the plasma membrane (Fig. 3 and 4), we tried to determine whether palmitoylation 
is indeed required for SNAP23 to appear on the plasma membrane in our system. We used two 
types of palmitoylation inhibitors, 2-bromopalmitate (2-BP) or cerulenin (Cr) (Resh, 2006), to 
block the palmitoylation of SNAP23 and examined the changes of SNAP23 localization on the 
plasma membrane. Our studies showed that treatment of cells with 2-bromopalmitate or cerulenin 
greatly reduced the plasma membrane-associated SNAP23 (Fig. 5A). Using the Acyl-Biotinyl 
Exchange assay, we found that the levels of palmitoylated SNAP23 proteins were significantly 
inhibited by these palmitoylation inhibitors (Fig. 5B). Similarly, these palmitoylation inhibitors 
also markedly diminished the palmitoylation levels of Yes (Fig. 5B). These studies again 
confirmed that SNAP23 is indeed palmitoylated in our cells, and the palmitoylation status affects 
SNAP23 intracellular localization. Notably, our studies revealed that SNAP23 staining on the 
plasma membrane disappeared after the treatment of these palmitoylation inhibitors with 
concurrent accumulation in the TGN region that overlapped with the TGN46 marker (Fig. 5A), 
indicating that SNAP23 is palmitoylated in the TGN and its trafficking out of the TGN requires a 
prior palmitoylation of the protein. Although there is a study suggesting that the palmitoylation of 
SNAP23 occurs on the plasma membrane (Weber et al., 2017), our data are consistent with the 
report showing that the SNAP23 palmitoylation occurs on Golgi (Salaun et al., 2005). Since 
palmitoylation inhibitors phenocopied the effects of ASM inactivation (comparing Fig. 4A and 5A) 
on the dynamic distribution of SNAP23 from the plasma membrane to the TGN, our studies 
strongly suggest that ASM regulates the palmitoylation-dependent vesicle transport of SNAP23 
from the TGN to the plasma membrane. 
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 ASM does not affect protein palmitoylation process itself 
Since treatment of cells with palmitoylation inhibitors phenocopied the effects of ASM 
inactivation on the distribution of SNAP23 on the plasma membrane and the TGN (Fig. 5A), it 
remains unclear whether loss of ASM affects the palmitoylation process itself. To determine 
whether ASM acts at the palmitoylation step or after palmitoylation of SNAP23, we directly tested 
whether loss of ASM affects palmitoylation of SNAP23 or other proteins using the Acyl-Biotinyl 
Exchange assay. We found that while treatment of cells with 2-bromopalmitate greatly inhibited 
the palmitoylation of SNAP23 and Yes, however, knocking down of ASM did not affect the 
palmitoylation levels of these proteins (Fig. 5B). Our studies thus indicate that ASM is not 
required for the palmitoylation reaction of SNAP23 or other proteins per se. Rather, ASM 
inactivation is likely to affect the association of SNAP23 and other palmitoylated proteins with 
certain membrane components in the TGN, causing the failure of these proteins to be transported 
out of the TGN.  
 
Palmitoylation mutants fail to partition in the ASM-regulated membrane fractions 
SNAP23 contains a centrally localized cluster of five cysteine residues, C79, C80, C83, C85, and 
C87 that are known be palmitoylated (Salaun et al., 2005). These five cysteine residues are also 
predicted to be palmitoylated according to the SwissPalm database analysis (Blanc et al., 2015). To 
further characterize the role of palmitoylation in SNAP23 in association with the ASM-sensitive 
DRM fractions, we have converted these cysteine residues to serine residues (C79S, C80S, C83S, 
C85S, and C87S), and the C->S mutant derivative should not be palmitoylated. We also mutated 
the cysteine residues at position 3 and 381 in Lyn to serines (C3S, C381S), since the cysteine 3 
residue is known to be palmitoylated (Kovarova et al., 2001), and both cysteine 3 and 381 are 
predicted to be palmitoylated according to the SwissPalm database analysis (Blanc et al., 2015). To 
determine the role of palmitoylation in regulation of DRM association, we examined and 
compared the behavioral differences of the Cys->Ser mutants of SNAP23 and Lyn to their wild-
type counterparts after ectopically expressing them in cells. To distinguish the ectopically 
expressed proteins from the endogenous ones, we have expressed the ectopically expressed 
proteins as GFP fusion proteins, with GFP tagged at the N-terminus of SNAP23 and the C-
terminus of Lyn, respectively (Fig. 6A and 6B). Expression of these proteins in U373-MG cells 
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revealed that the Cys->Ser mutations in SNAP23 and Lyn greatly reduced their respective 
palmitoylation levels based on the Acyl-Biotinyl Exchange assay, as compared to their wild-type 
counterparts (Fig. 6A). In addition, while the exogenous GFP-SNAP23(CS) or GFP-Lyn(CS) 
mutant proteins failed to be palmitoylated, the palmitoylation of the endogenous SNAP23 and Lyn 
proteins are not affected, serving as a positive control for each cell line (Fig. 6A). In addition, we 
found that these palmitoylation defective mutants of SNAP23 and Lyn also failed to associate with 
the DRM fractions as analyzed by the discontinuous sucrose gradient ultracentrifugation method 
(Fig. 6B). In comparison, the distribution of the endogenous SNAP23 in these DRM fractions was 
sensitive to the ASM inhibitor desipramine (Fig. 6C), in a manner similar to the behavior of Yes 
(Fig. 1B). These studies showed that the palmitoylation of SNAP23 and Lyn is required for their 
association with the ASM-regulated DRM compartments. By fluorescence microscopy, our studies 
revealed that while the wild-type GFP-SNAP23 and GFP-Lyn proteins were both found on the 
plasma membrane, their palmitoylation-defective mutants failed to appear on the plasma 
membrane (Fig. 6D). In fact, we found that these mutant proteins accumulated intracellularly, 
likely in the Golgi area (Fig. 6D). Here again, our studies indicate that the behavior of these 
palmitoylation-defective mutants of SNAP23 and Lyn phenocopied that of their endogenous 
proteins in response to the ASM inactivation (Fig. 4 and 6). Thus, our studies provide strong 
evidence that palmitoylation of these proteins is responsible for their association with the ASM-
sensitive DRM fractions, which correlates with their ability to be localized on the plasma 
membrane, likely through trafficking out of the TGN. 
 
Both ASM and ceramides are present on the cell surface 
We wondered if ASM might be localized on the plasma membrane, a location to allow an easy 
access to its substrates, sphingomyelins, which are asymmetrically localized on the outer-leaflet of 
the plasma membrane (Lopez-Montero et al., 2010; van Blitterswijk et al., 2003). We used specific 
anti-ASM antibodies to examine the cellular location of ASM. Our studies revealed that the ASM 
protein is indeed found on the plasma membrane (Fig. 7A). The immunostaining of ASM on the 
plasma membrane was specific since these stainings were abolished in cells treated with ASM 
siRNAs or ASM inhibitor desipramine (Fig. 7A). Earlier studies have shown that when cells are 
exposed to various lethal doses of stress stimuli, the ASM protein is translocated from intracellular 
store(s) to the outer leaflet of the plasma membrane (Cremesti et al., 2001; Grassme et al., 2003; 
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Tam et al., 2010). Our data, however, indicate that ASM is normally present on the plasma 
membrane in actively growing U373-MG cells even without the presence of stress stimuli. To 
further determine that ASM protein is present on the plasma membrane, we immunostained live 
cells directly using anti-ASM antibody without prior fixation. Indeed, plasma membrane ASM 
staining was present in the control cells but not in the cells pretreated with ASM siRNAs (Fig. 7C). 
Under this staining condition, there are some staining in the perinuclear regions in both control 
cells and cells treated with ASM siRNAs, which might have occurred due to the antibodies being 
endocytosed during the live staining process (Fig. 7C).  
 
We also used a specific monoclonal anti-ceramide antibody to determine whether ceramides, the 
products from the action of ASM on sphingomyelins, are found on the plasma membrane. Our 
immunostaining of ceramides revealed that ceramides are indeed present on the plasma membrane 
and such ceramide-immunostaining on the cell membrane surface was abolished in cells treated 
with either ASM siRNAs or ASM inhibitor desipramine (Fig. 7A). The effects of ASM on the 
plasma membrane lipids were selective, as we did not observe significant staining changes of GM1, 
a member of gangliosides, on the plasma membrane in cells treated with ASM siRNAs or ASM 
inhibitor desipramine (Fig. 7B). Our detection of ceramides in the plasma membrane is consistent 
with earlier reports that ceramides are detected as a patch region on the plasma membrane, 
although those ceramide-stained areas were only found on cells when challenged with strong stress 
stimuli (Cremesti et al., 2001; Grassme et al., 2003; Tam et al., 2010). 
 
Rescuing the ASM siRNA-mediated trafficking block of SNAP23 by the extracellular ASM 
enzyme 
Since ASM and ceramides are detected on the plasma membrane (Fig. 7A-7C), we wondered 
whether the extracellularly localized ASM could indeed act through ceramides on the plasma 
membrane to regulate the intracellular trafficking of palmitoylated proteins from the Golgi to the 
plasma membrane. To test this possibility, we performed a “rescue” experiment to determine 
whether an exogenously supplied recombinant ASM enzyme can rescue the SNAP23 trafficking 
defect in the ASM-deficient cells.  For this experiment, we first silenced the ASM gene expression 
by specific ASM siRNAs for 48 hours, and then incubated these ASM-deficient cells with the 
active recombinant human ASM protein (rASM), or left untreated (control). As shown in Fig. 7D, 
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treatment of cells with ASM siRNAs, but not the control siRNAs, caused the disappearance of the 
plasma membrane staining of SNAP23.  However, externally addition of the recombinant ASM 
protein to the ASM siRNA-treated cells was sufficient to allow the re-appearance of SNAP23 on 
the plasma membrane (Fig. 7D, and quantification in 7E). These results demonstrate that the 
presence of ASM enzyme outside of the cell is able to reverse the phenotypes of trapping SNAP23 
in the TGN in the ASM-deficient cells, allowing SNAP23 to exit the TGN and then to traffic to the 
plasma membrane. These experiments suggest that ASM protein may function extracellularly to 
produce ceramides by hydrolyzing sphingomyelin on the outer leaflet on the plasma membrane to 
regulate the intracellular trafficking of the Golgi-localized palmitoylated proteins.  
 
Discussion 
In this report, we present our studies on using semi-quantitative mass-spectrometry analyses to 
interrogate the proteins that are associated with the detergent (Brij58)-resistant membrane fractions 
(DRMs). While more than 100 ASM-sensitive DRM-associated proteins were identified in the 
actively growing U373-MG cells, our investigation revealed that a major fraction (60%) of these 
proteins are palmitoylated proteins, including SFKs, Ras-family GTPases, Rab-family GTPases 
and proteins involved in vesicular trafficking such as SNAP23 and syntaxins (Fig. 2B, Suppl. 
Table 3). Our results indicate that ASM and its catalytic products, ceremides, are required for the 
association of these palmitoylated proteins to the DRMs, both at the plasma membrane and at the 
Golgi membranes or endosome membranes. Our characterization of the palmitoylation-defective 
mutants of SNAP23 and Lyn suggests that the palmitoyl moiety in these proteins confers their 
association to the ASM-sensitive DRMs.  
 
Our studies have also revealed a critical role of ASM in regulation of the trafficking of 
palmitoylated proteins. We found that inactivation of ASM causes a number of proteins, including 
SNAP23, Lyn, Yes, G(i)2 and CD59, to disappear on the plasma membrane, and concurrently 
promotes the accumulation of these proteins intracellularly (Fig. 3). Using SNAP23 as an example, 
we showed that ASM deficiency leads to SNAP23 accumulation at the Golgi, which can be 
phenocopied by treating cells with palmitoylation inhibitors or by mutation of the palmitoylation 
sites in SNAP23 (Fig. 4-6). Similar effect was observed with Lyn (Fig. 6). While it is possible that 
ASM deficiency causes a defect in palmitoylation of SNAP23 and Lyn to account for their Golgi 
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transport defects, our subsequent characterization showed that ASM did not affect the 
palmitoylation itself. Instead, ASM inactivation leads to a trafficking defect of these proteins to 
exit out of the TGN after they are palmitoylated. Interestingly, we have recently found that ASM 
deficiency blocked the trafficking of the MET receptor protein tyrosine kinase out of the Golgi to 
the plasma membrane, while the transport of a viral protein VSVG was not affected by ASM 
inactivation (Zhu et al., 2016). Therefore, it is possible that ASM is required for the selective 
transport of certain cargos from specific subdomains in the Golgi. In fact, the lipid microdomains 
of sphinomeylins and cholesterols have been proposed to act as a sorting platform on the Golgi to 
help proteins transport (Schuck and Simons, 2004). Our studies have added one additional layer of 
complexity to this model. It can be envisioned that ceramides on the Golgi membrane can provide 
a favorable lipid microenvironment to allow the palmitoylated proteins to interact with the Golgi 
transport machinery, although this case is to facilitate the transport carrier formation, rather than 
sorting per se. It worth pointing out that our ASM-dependent DRM proteome analysis has 
identified many ASM-regulated proteins that are involved in various processes of vesicular 
transport, such as SNARE proteins and members of Rab GTPases. Future studies are required to 
unravel the specific roles of ceramides in the regulation of Golgi transport.  
 
Our studies have shown that ASM protein and ceramides are present on the plasma membrane in 
the actively growing cells (Fig. 7). This is both consistent but different from the previous reports, 
which showed that lethal doses of stress stimuli could stimulate the transport of ASM from the 
intracellular stores, likely the luminal side of the lysosomes, to the extracytoplasmic side of the 
plasma membrane (Cremesti et al., 2001; Grassme et al., 2003; Tam et al., 2010). Specifically, we 
found that high levels of ASM proteins and ceramides are present on the plasma membrane in 
actively growing glioblastoma cells, even without exposure to stress stimuli. The presence of ASM 
and ceramides on the plasma membrane of actively growing cells suggests that the enzyme and the 
lipids have a normal function in cells, which is consistent with our genetic studies in C. elegans 
demonstrating that the ASM homolog is required for the IGF-1R-like signaling pathway under 
physiological conditions (Kim and Sun, 2012). Importantly, our rescue experiments revealed that 
externally added ASM on the extracellular leaflet of the plasma membrane is sufficient to regulate 
the intracellular Golgi transport of the palmitoylated proteins (Fig. 6C). We believe that ASM can 
produce ceramides on the plasma membrane, which then communicate with the Golgi to regulate 
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the transporting of the palmitoylated proteins. It has been reported that synthetic ceramide analog, 
C6-ceramide, can be taken up by the cells from culture medium to be transported back to the Golgi 
(Martin and Pagano, 1994). In our model (shown in Fig. 7F), ASM acts at the outer-leaflet of the 
plasma membrane to convert sphingomyelins to ceramides. While sphingomyelins are mainly on 
the outer leaflet of the plasma membrane, ceramides can flip-flop and are therefore present on both 
leaflets. In addition to the self-association property of ceramides, the removal of the 
phosphorylcholine head group on the sphingomyelin could also make the otherwise deeply buried 
cholesterol accessible. Ceramides can retrogradely traffic back to TGN. On the Golgi membrane, 
ceramides recruit the palmitoylated proteins such as SNAP23 and Lyn to facilitate the transport of 
these proteins out of the TGN. When ASM is inactivated, SNAP23 and Lyn are trapped in the 
TGN, due to the lack of the ceramides on the Golgi membrane that are essential for the transport of 
the palmitoylated proteins out of the TGN. Interestingly, as ASM itself can be found at the plasma 
membrane in actively growing cells, a location that may allow ASM activity to be regulated by 
extracellular growth factors, cell attachment and pH environment, which can in turn modulate the 
function of plasma membrane or the Golgi to govern cell signaling and intracellular Golgi 
transport processes in a temporally and spatially controlled manner.   
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Experimental Procedure: 
 
Cells, antibodies, and reagents: 
Human glioblastoma U373-MG cells were obtained from American Type Culture Collection 
(ATCC) and were cultured in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) 
supplemented with 10% fetal bovine serum, penicillin and streptomycin at 37ºC, 5% CO2. 
Antibodies for ASM (H-181, sc-11352), Lyn (H-6, sc-7274), Flotillin-2 (clone B-6, sc-28320), 
VAMP3 (N-12, sc-18208), and G(i)2 (L5, sc-13534) were purchased from Santa Cruz 
Biotechnology; antibodies for SNAP23 (ab4114), Rab14 (ab40938) and GM1 (ab23943) were 
from Abcam; antibodies for Rab7 (#9367) and Yes (#2734) were from Cell Signaling; antibodies 
for TGN38 (#610898), GM130 (#610822), CD59 (clone p282, H19), Fyn (clone 25/Fyn) and 
Fixation and Permeabilization Solution (#554722) were from BD Biosciences; antibodies for 
ASM/SMPD1 (AF5348, goat IgG), ASM/SMPD1 (MAB5348, mouse IgG2A), and recombinant 
human ASM/SMPD1 protein (#5348-PD) were from R&D Systems; anti-ceramide mouse 
monoclonal antibody (clone MID15B4) was from Enzo Life Sciences; anti-Ras (clone 9A11.2, 
recognizes H, N, K-Ras) mouse monoclonal antibody was from EMD Millipore. Alexa Fluor 488-
conjugated goat anti-mouse IgG, 488-conjugated anti-rabbit IgG, Alexa Fluor 647-conjugated anti-
mouse IgG, Alexa Fluor 647-conjugated anti-rabbit IgG antibodies, ChromPure Rabbit IgG (011-
000-003), ChromPure Mouse IgG (015-000-003), ChromPure Goat IgG (005-000-003), and 
normal goat serum (005-000-121) were from Jackson Immunologicals. Streptavidin-HRP was 
from Pierce (Thermo), protein A and G Sepharoses were from GE Healthcare. DAPI (4', 6-
diamidino-2-phenylindole, 32670), desipramine hydrochloride (D3900), 2-bromopalmitate 
(238422), cerulenin (C2389), cycloheximide, and methyl-β-cyclodextrin (MβCD, M7439) were 
from Sigma-Aldrich.  
 
Small RNA (siRNA) interference and compound treatment  
All siRNAs were synthesized by Dharmacon. Sequences of siRNAs: Human Luciferase siRNA: 5'-
CGTACGCGGAATACTTCGA-3', Human ASM siASM-1: 5'-CTACCTACATC 
GGCCTTAA-3', siRNA-siASM-2: 5'-AGACCTACATCCTGAATCT-3'. U373-MG Cells were 
transfected with 50 nM siRNAs using oligofectamine (Invitrogen) for 48-72 hours. For 
immunostaining, cells were trysinized at 48hr after transfection and cultured on 24-well plate for 
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overnight growth.  For drug treatment, cells were typically treated with 10 mM Methyl-β-
cyclodextrin (MβCD) for 1 hour; 25 M desipramine for 4 hours or overnight, 100 M 2-
bromopalmitate for 6 hours, and 5 g/ml cerulenin for 6 hours. Immunfluorescence staining and 
microscopy were conducted as described below. Immunoprecipitation and Western blotting were 
conducted as described previously (Zhang et al., 2013). 
 
cDNA Expression constructs 
The cDNA encoding SNAP23 was synthesized and cloned into the pcDNA3.1-N-eGFP vector to 
derive the pcDNA-N-GFP-SNAP23 construct (service provided by GenScript, Piscataway, NJ). 
Cys->Ser mutations were subsequently introduced at the amino acid 79, 80, 83, 85 and 87 in the 
SNAP23 cDNA. pEGFP-N1-human Lyn–GFP was a gift from Anna Huttenlocher (Addgene 
plasmid # 35958) (Yoo et al., 2011). Cys->Ser mutations were subsequently introduced at the 
amino acid 3 and 381 in the Lyn cDNA. Site-directed mutagenesis of SNAP23 and Lyn to 
introduce Cys->Ser mutations were conducted by GenScript (Piscataway, NJ) and all cDNAs were 
confirmed by sequencing. The expression plasmids were transfected to U373-MG cells by 
Lipofectamine 2000 and the stable transfectants were obtained following selection for G418 
resistance.  
 
Sphingomyelinase assay 
Sphingomyelinase assay was conducted according to described (Horinouchi et al., 1995; Otterbach 
and Stoffel, 1995). Briefly, cells were lysed in a buffer containing 0.2% Triton X-100, 100 mM 
sodium acetate, pH 5.2, 1mM EDTA and with protease inhibitor mixes (Sigma), and sonicated 
briefly (10s, three times). Cell debris was pelleted by centrifugation at 13,000 rpm for 5 minutes at 
4°C. Samples were normalized for protein concentration using the Bio-Rad protein assay. The 
substrate, [Choline-Methyl-14C] sphingomyelin (0.02mCi/ml, NEC663010UC, PerkinElmer), was 
dried and re-suspended in the assay buffer (250 mM sodium acetate, pH 5.2, 1mM EDTA, 0.2% 
Triton X-100) and sonicated. Then 100 l of sphingomyelin substrate and 100 l of clarified cell 
lysates were incubated at 37°C for 30-60 minutes with occasional vortexing. The enzyme reaction 
was terminated by addition of 0.8 ml of CHCl3: MeOH (2:1, v/v) followed by 0.2 ml of water. 
Samples were vortexed, centrifuged at 5,000Xg for 95 minutes, and 0.3 ml of upper aqueous phase 
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was removed for liquid scintillation counting. The assay was linear with time and protein 
concentration and the maximum substrate hydrolysis was less than 10%. 
 
Isolation of Brij58-resistant membrane fractions  
The Brij-resistant membrane and soluble fractions were isolated according to the described 
procedure (Giurisato et al., 2003; Montixi et al., 1998; Roper et al., 2000). U373-MG cells grown 
on the 100 mm tissue culture dishes were washed with ice-cold 1XPBS for 2 times and then 
incubated with 250 l ice-cold MBS buffer (25 mM MES, pH6.5, 150 mM NaCl, 50 mM NaF, 2 
mM sodium pyrophosphate, 1 mM sodium vanadate, 20 mM -glycerophosphate) containing 1% 
Brij58 and the protease inhibitor mixes (10 g/ml aprotinin, 1mM benzamidine, and 10 g/ml 
leupeptin). Cells were then scraped off the dish and homogenized with a Dounce homogenizer (1 
ml) with 20 strokes. Two 100 mm dishes of cells were used for each sample. Cell debris was 
clarified by centrifugation at 960xg for 10 minutes at 4 °C and the clarified cell extracts were 
normalized for equal amount of total proteins in each sample in 500 l total volume. The lysates 
were mixed with equal volume (500 l) of 80% sucrose in the MBS buffer (sucrose-MBS) with 1% 
Brij58 to obtain 40% final sucrose concentration. This mixture was loaded under the 3.2 ml of 35% 
sucrose-MBS in the centrifuge tube; and an additional 0.80 ml of 5% sucrose-MBS was added 
slowly on top of 35% sucrose-MBS to form a discontinuous sucrose gradient of 5%, 35%, and 40% 
for buoyant density gradient ultracentrifugation. The sucrose gradients were centrifuged in a 
Beckman SW55 Ti swinging rotor at 41,000 rpm, 40C, for 18 hours. After centrifugation, 300 l 
per fraction was taken from the top (low density, fraction #1) to the bottom (high density, fraction 
#16) of the centrifuge tube. The Brij58-resistant membrane fractions were isolated as a band from 
the 5% to 35% sucrose interference (fractions #1-#4), where Brij58-soluble fractions were in the 
bottom fractions (fractions #13-#16). By Bradford protein concentration determination, total 
protein concentration in pooled fractions of #1-#4 is only 1% of the total protein concentration in 
the pooled fractions of #13-#16. Proteins associated with the fractions were analyzed by Western 
blotting with specific antibodies or processed for mass spectrometry proteomic analysis. 
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Protein gel electrophoresis and in-gel trypsin digestion 
Fraction #1-4 from the ultracentrifugation were pooled, and concentrated by Amicon Ultra 
centrifugal filters (10 kDa cut-off, Millipore) then resolved on a 4-12.5% gradient Nu-PAGE gel 
(Invitrogen). Proteins were stained with Coomassie Blue, and extracted from the gel by first slicing 
the gel to twenty-four equally spaced gel pieces from the bottom to the top of the gel (10-300 kDa). 
Individual gel slices were destained with 25 mM NH4HCO3 in 50% acetonitrile (ACN), reduced 
with 20 mM dithiothreitol in 25 mM NH4HCO3 for 1 hour at 37°C, and alkylated with 55 mM 
iodoacetamide in 25 mM NH4HCO3 in the dark for 1 hour at room temperature. After washing, the 
gel slices were dehydrated with ACN and dried using a Speed-Vacuum system. Mass 
spectrometry-grade trypsin (Promega) was incubated with each gel slice overnight at 37℃. The 
supernatant was collected and dried using a Speed-Vacuum for subsequent liquid chromatography 
mass spectrometry (LC-MS/MS) analysis. 
  
Mass spectrometry-based proteomic analysis of proteins 
Tryptic peptides derived from each gel slice were analyzed by an on-line C18 nano-flow reversed- 
phase liquid chromatography instrument (Easy nano-liquid chromatography) connected to an LTQ 
Orbitrap XL mass spectrometer (Thermo Scientific). Samples were concentrated onto an in-house 
packed 100-nm-inner diameter x 1-cm C18 column (Magic C18, 5 µm, 300 Å, Michrom 
Bioresources Inc.) then separated on 50-nm-inner diameter x 15-cm C18 column at 300 nl/min 
with 75min linear gradients from 0 to 35% acetonitrile in 0.1% formic acid. The LC eluent was 
directly nanosprayed into an LTQ Orbitrap XL mass spectrometer (Thermo Scientific) with an 
ionization voltage of 2.2 KV. During the chromatographic separation, the LTQ Orbitrap XL is 
operated in a data-dependent mode and under the direct control of Xcalibur (Thermo). The mass 
spectrometry (MS) data were acquired using the following parameters: 5 data-dependent collision-
induced dissociation MS2 scan survey in the linear ion trap per every full scan in the Orbitrap with 
the resolution set to a value of 60,000; 35% normalized collision energy in CID; +/-2 Da isolation 
window. 
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Proteomic data analysis 
Proteomic profiling data were first analyzed by QualBrowser in Xcalibur and Proteome Discoverer 
to identify proteins with unique peptides, and followed by analysis with the Scaffold software 
(Proteome Software, Oregan, Portland) which uses advanced algorithms to improve statistical 
significance. Only proteins that passed the protein probability threshold above 99%, peptide 
probability threshold above 95%, and contained at least 1 unique peptide were taken for label-free 
quantitation. Total number of high quality peptides identified in the DMSO control or 
desipramine-treated samples are 3345 and 3644, respectively, which were then subjected to spectra 
counting. The spectrum number from each experiment was exported to Excel spreadsheets and the 
relative abundance of proteins were calculated based on the published protocols. Details are 
described below. 
 
The Thermo .raw files were analyzed by Proteome Discoverer (version 1.0) which searched 
against IPI human database (v3.75; 89,486sequences) using following parameters: two tryptic 
mass cleavages, 10 ppm precursor ion mass tolerance, 0.8Da fragment ion mass tolerance, fix 
modification of carbamidomethyl on cysteines, and variable protein modification of oxidation on 
methionines. For protein identification and label-free quantitation, the .msf files generated from 
Proteome Discoverer were subsequently analyzed by Scaffold 3 software (version 3.0; Proteome 
Software Inc., Portland Oregon).  
 
Results were filtered on Scaffold to achieve a protein probability < 1.0% and peptide probability < 
5.0% with at least one unique peptide identification. The spectra counts were used to calculate the 
relative abundance of proteins were calculated based on the published protocols(Liu et al., 2004; 
Old et al., 2005): RSC =log2 [(n2 + f) / (n1 + f )] + log2[(t1 -n1 +f )/(t2 - n2 + f )], where, for each 
protein, RSC is the log2 ratio of abundance between Samples 1 and 2; n1 and n2 are spectral counts 
for the protein in Samples 1 and 2, respectively; t1 and t2 are total numbers of spectra over all 
proteins in the two samples; and ƒ is a correction factor set to 1.25. The candidate ASM-dependent 
membrane-associated proteins are defined as the proteins that were sensitive to ASM siRNA using 
a threshold of 2.0 and at least two unique peptides, and this group of proteins is defined as the high 
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confidence group. In addition, there are a group of proteins which contains at least one unique 
peptide, with a change of protein abundance threshold of 1.8, and this group of proteins is 
considered low confidence group.  
 
Immunofluorescence microscope image acquisition  
Cells were cultured on 24-well plate for 24 hours and then the cells were transfected with specific 
ASM siRNAs or treated with specific chemical compound for indicated times.  Cells were washed 
briefly with PBS and immediately fixed with BD Fixation and Permeabilization Solution for 30 
minutes. After incubated with the primary antibodies overnight at 4ºC, cells were washed in PBS 
and incubated with fluorescence labeled secondary antibodies or with biotin-streptavidin system at 
room temperature. Cells were staining with PBS containing 1μg/ml DAPI for DNA counter 
staining. Images were captured by an automated confocal microscope system with high content 
screen capability, OperaTM LX (Perkin Elmer Inc.) with 24x (NA1.0) or 40x (NA1.1) water 
immersion lenses. Images were processed by using the onboard Acapella software. Alternatively, 
images were acquired by Nikon A1R+ confocal microscope using 40X oil immersion lens (NA1.3), 
as described (Zhu et al., 2016). Quantitations of the relative proteins abundance on the plasma 
membrane are carried out using the fluorescence images and ImageJ software (Schindelin et al., 
2012), as described (Zhu et al., 2016). ChromPure Rabbit IgG or ChromPure Mouse IgG was used 
as negative controls. 
 
The Acyl-Biotinyl Exchange (ABE) Assay for palmitoylated proteins 
1x108 active growing U373-MG cells were collected by centrifugation and then re-suspended in 3 
ml ice-cold lysis buffer containing 10 mM N-ethylmaleimide (NEM, freshly diluted from 1M 
stock prepared in ethanol), 2x protease inhibitor mix (Sigma) and 2 mM phenylmethylsulfonyl 
fluoride (PMSF), and then homogenized with 25 strokes of a Dounce homogenizer. Triton X-100 
was added to 1.7% and the lysate was incubated with gentle mixing for 1 hour at 4ºC. Cell debris 
was removed by centrifugation at 5000 rpm for 10 minutes. The ABE assays were performed 
according to (Kang et al., 2008; Roth et al., 2006). Briefly, proteins were precipitated by a 
chloroform-methanol mixture and then treated extensively with N-ethylmaleimide (NEM) to block 
free thiol groups. After reaction, free NEM was removed by sequential chloroform-methanol (CM) 
precipitation. In the NEM-blocked lysates, the palmitoyl group of palmitoylated proteins is 
B
io
lo
gy
 O
pe
n 
• 
A
cc
ep
te
d 
m
an
us
cr
ip
t
 at University of Nevada - Las Vegas on September 17, 2019http://bio.biologists.org/Downloaded from 
removed from the palmitoylated thio groups of cysteine residues by treating the lysates with or 
without hydroxylamine (HA). The HA-exposed thio groups were labeled with biotin-HPDP and 
the free biotin-HPDP is removed by precipitation. The precipitated proteins were solubilized and 
the biotin-HPDP modified proteins were incubated with streptavidin-agarose resins. The bound 
proteins on the streptavidin-agarose beads were extensively washed (>four times) with the lysis 
buffer and then bound proteins were separated in SDS-PAGE. Specific proteins in the streptavidin-
agarose beads were identified by Western blotting with specific antibodies.  
 
Statistical analysis: 
Experiments were usually performed with at least three independent repeats (biological replicates) 
to ensure the results.  For cell number assays, triplicated repeats in the same set of cells were 
measured and the experiments usually repeated in three independent experiments with different 
cultured cells. Quantitative data are expressed by bar graph and standard deviations (S.D.) are 
expressed as mean and error bars. For siRNA-mediated knockdown or drug treatment experiments, 
statistically significant differences between means of control and knockdown/drug treated were 
compared using a two-tailed equal-variance independent t-test(Fay and Gerow, 2013). Different 
data sets were considered to be statistically significant when the P-value was <0.01. 
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Figures 
 
 
 
 
Figure 1. Fractionation of the ASM-regulated membrane-associated proteins by 
discontinuous sucrose gradient ultracentrifugation.  
A. A schematic workflow of the discontinuous sucrose gradient fractionation procedure.  
B. The distribution of tyrosine kinases IGF-1R and Yes in the discontinuous sucrose gradient in 
control (DMSO) and desipramine (Desi, 25 μM, 12 hours) treated U373-MG cells by anti-IGF-1R 
and anti-Yes antibody immunoblotting. Flotillin was used as a lipid raft marker. Fractions were 
collected from the top (fraction #1) to the bottom of the gradient (fraction #16). The distribution of 
IGF-1R or Yes was reduced in the detergent resistant membrane (DRM) fractions (#1-#4) after 
ASM inhibition.  
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C. Loss of ASM reduced the levels of Yes in the detergent resistant membrane fraction. U373-MG 
cells were transfected with 50 nM control (luciferase, siLuc) and ASM siRNAs (siASM) for 48 
hours and the cells were harvested in the Brij58-containing lysis buffer and fractionated and 
analyzed as in B.  
D. The same as in B except U373-MG cells were treated control (PBS) or 10 mM MβCD for 1 
hour and the cells were harvested in the Brij58-containing lysis buffer, fractionated, and analyzed 
as in B.  
E The reduction of ASM activities in the desipramine-treated cells or the ASM siRNAs-treated 
cells were determined using the sphingomyelinase assay, as compared with control cells. Data are 
means ± s.d. (n=3) with three independent repeats. 
F. Knockdown efficiency of two independent ASM siRNAs on the ASM protein levels in U373-
MG cells. ASM was immunoprecipitated from the lysates and then analyzed by Western blot by an 
anti-ASM antibodies. 
G. Independent verification of the effects of ASM siRNAs, desipramine, and MβCD on the 
distribution of Yes in discontinuous sucrose gradient. U373-MG cells were transfected with 50 nM 
control (siLuc) and two independent ASM siRNAs for 48 hours or treated with 25 μM desipramine 
for 10 hours or 10 mM MβCD for 1 hour. The cells were harvested in the Brij58-containing lysis  
buffer and fractionated. The distribution of Yes was monitored in the pooled DRM fractions 
(fraction #1-#4) or soluble fractions (fraction #13-#16) by Western blotting. 
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Figure 2. Mass spectrometry-based proteomic analysis of ASM-regulated DRM-associated 
proteins.  
A. A schematic illustration of the proteomic procedure to analyze ASM-regulated DRM-associated 
proteins. 
B. A partial list of proteins identified the ASM-sensitive DRM proteome. Proteins identified are 
cross-referenced to the palmitoyl-proteome database (SwissPalm) and 65 proteins are found to be 
known palmitoylated proteins (Suppl Table 3). Selected proteins from the Supplmentary Table 3 
are listed here. Semi-quantitative mass-spectrometry data, fold of protein abundance change 
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between control siLuciferase and siASM, as well as numbers of peptides identified in each 
condition, for the listed proteins are shown in the middle columns. The numbers of articles that 
reported the particular protein found in the palmitoyl-proteome is indicated in the last column.  
C. A pie illustration to indicate the functional categories and the percentage of proteins in each 
category. Analysis is based on the identified palmitoylated proteins in the ASM-sensitive DRM 
proteome (Supplmentary Table 3).  
D. Validation of the mass-spectrometry-based quantitation by Western blot analysis. Selected 
proteins from the list in panel B were subjected to Western blot analysis using corresponding 
antibodies. Cells were treated with ASM siRNA or desipramine, or corresponding controls, and 
subjected by discontinuous sucrose gradient ultracentrifugation analysis. The pooled DRM 
fractions are analyzed as described in Fig. 1G.  
E. The Acyl-Biotinyl Exchange (ABE) assay to detect protein palmitoylation. Lysates from U373-
MG cells were exposed to NEM to block all unmodified free thio groups (-SH) in the cysteine 
residues. The NEM-treated cell lysates were next exposed to hydroxylamine (HA), or left 
untreated. Both groups were then incubated with biotin-HPDP and subsequently pulled down by 
the streptavidin-agarose resins, followed by Western blot analysis. Palmitoylated protein are 
enriched by HA treatment as compared to the no prior HA treatment group. Whole cell lysates 
(WCL) were used as control.  
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 Figure 3. ASM-deficiency reduces the plasma membrane localization of the palmitoylated 
proteins.  
A and B. Selective inactivation of ASM by two independent siRNA (A) or ASM inhibitor 
desipramine (B) reduced the plasma  
membrane localization of SNAP23, Gα(i)2, and Yes, as compared with cells treated with 
corresponding controls. Cells were  
processed by immunostaining with specific antibodies and examined by fluorescence microscopy. 
The plasma membrane staining of specific proteins is indicated by arrows. 
C and D. Quantification of cell imaging data from A and B. Inhibition of ASM leads to strong 
reduction of SNAP23, Gα(i)2, and Yes on cell membranes. Relative plasma membrane staining 
was obtained by quantitation of the intensity of the fluorescence staining on the plasma membrane 
as compared with the intensity of the staining in the whole cells (200 cells were measured for each 
condition), using ImageJ software. Experiments were repeated three times to derive the average  
(the mean) of the relative abundance for the plasma membrane associated protein  (statistical 
significant, P<0.01, Student’s t-test). 
E. Silencing ASM also reduces the plasma membrane staining of Lyn and CD59. Cells were 
treated with two independent ASM siRNAs, and stained with antibodies for Lyn, or CD59, 
respectively (green), and countered stained with DAPI, a DNA binding dye to stain the nucleus 
(blue). 
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Figure 4: Inactivation of ASM blocks the plasma membrane delivery of SNAP23 with 
concurrent accumulation in trans-Golgi network (TGN). 
A and B. U373-MG cells were transfected with 50 nM control (Luc) or two independent ASM 
siRNAs for 48 hours. Cells were co-immunostained with anti-SNAP23 (red) and TGN marker 
TGN46 (green) in panel A, or SNAP23 (red) and cis-Golgi marker GM130 (green) in panel B. 
Inactivation of ASM leads SNAP23 to disappear from the plasma membrane (indicated by arrows) 
and accumulated intracellularly (indicated by arrowheads) that are co-localized with TGN46 
(yellow) but not with GM130. Inset: boxed regions are enlarged.  Scale bars, 10 m.  
C. U373-MG cells were treated with cycloheximide (50 μg/ml, CHX), or vehicle DMSO for 6 
hours, and stained as in panel A. 
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Figure 5. Palmitoylation regulates the plasma membrane delivery and membrane-association 
of palmitoylated proteins.  
A. Palmitoylation inhibitors block the appearance of SNAP23 on the plasma membrane and cause 
SNAP23 accumulation in the TGN. U373-MG cells were treated with palmitoylation inhibitors 2-
bromopalmitate (2-BP, 100 µM) or cerulenin (Cr, 5 µg/ml) for 6 hours. Cells were co-
immunostained for  SNAP23 (red) and the TGN marker TGN46 (green), and counter-stained with 
DAPI for nuclei (blue). Both drug treatment lead to a disappearance of SNAP23 on the plasma 
membrane and the co-localization of SNAP23 with TGN46 (yellow), indicating trapping of 
SNAP23 in the TGN. 
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B. Inactivation of ASM does not affect protein palmitoylation. Palmitoylation of SNAP23 and Yes 
was each greatly reduced after treatment of cells with 2-bromopalmitate (upper panels) but not 
after ASM knockdown. U373-MG cells were treated with 100 µM 2-bromopalmitate (2-BP) for 6 
hours or transfected with 50 nM control and ASM siRNAs for 48 hours. Palmitoylation of  
SNAP23 and Yes were analyzed using the ABE assay, as in Fig. 2E. 
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Figure 6. DRM-association and intracellular localization of the palmitoylation-defective 
SNAP23 and Lyn. 
A. Mutations of specific cysteines in SNAP23 and Lyn greatly reduced their palmitoylation. Wild-
type (wt) and cysteine to serine (CS) mutants of SNAP23 and LYN were expressed as GFP-
SNAP23 and GFP-Lyn fusion proteins, with GFP tagged at the N-terminus of SNAP23 and C-
terminus of Lyn, respectively. Expression constructs were stably transfected into U373-MG cells. 
The cell lysates were prepared and palmitoylation of the wild-type and CS mutants were analyzed 
using the ABE assay as in Fig. 2E. While the exogenous CS mutant of SNAP23 and Lyn have 
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greatly reduced palmitoyltion levels, the palmitoylation status of the endogenous SNAP23 and Lyn 
are not affected, further serving as controls.  
B. Cysteine mutants of SNAP23 and Lyn failed to associate with the detergent Brij58-resistant 
membrane fractions (DRMs). Wild-type (wt) and CS mutants of GFP-SNAP23 and GFP-Lyn 
proteins were stably transfected into U373-MG cells, respectively. The cells were lysed in Brij58-
containing lysis buffer and fractionated in the discontinuous sucrose gradient ultracentrifugation, 
as in Fig. 1B, and the pooled fractions were examined by Western blot analysis, as described in Fig. 
1G. Only the wild-type but not the CS mutant proteins are found in the DRM fractions, while the 
CS mutant proteins are found mostly in the pooled soluble fractions. 
C. Association of SNAP23 with the detergent Brij58-resistant membrane fractions (DRMs) is 
sensitive to the ASM inhibitor desipramine. U373-MG cells were treated with the ASM inhibitor 
desipramine or vehicle control DMSO for 12 hours. Lysates were prepared in the Brij58 lysis 
buffer, and subjected to the sucrose discontinuous sucrose gradient ultracentrifugation as described 
in Fig. 1B. The fractions were analyzed by Western blot analysis using anti-SNAP23 antibodies. 
D. CS mutants of GFP-SNAP23 and GFP-Lyn failed to appear on the plasma membrane and were 
accumulated in the intracellular compartment. Wild-type (wt) and CS mutants of GFP-SNAP23 
and GFP-Lyn constructs were transfected into U373-MG cells. The localization of the GFP-tagged 
ectopically expressed proteins on the plasma membrane and intracellular compartment was  
examined by fluorescence microscopy. Scale bars, 10 m. 
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Figure 7. ASM acts at the plasma membrane to regulate the intracellular trafficking of 
palmitoylated proteins.  
A. U373-MG cells were treated with 50 nM control and two independent ASM siRNAs for 48 
hours. Alternatively, cells were treated with 25 μM desipramine or DMSO for 12 hours. The 
localization of ASM and its catalytic product, ceramide, was examined by specific anti-ASM 
and anti-ceramide antibody immunostaining. The plasma membrane staining of both ASM and 
ceramide (indicated by arrows) disappeared in cells after treatment with ASM siRNAs or with the 
ASM inhibitor desipramine. 
B. The distribution of ganglioside GM1 on the plasma membrane is not affected by ASM 
inactivation. The experiments were conducted similarly as panel A except that cells were 
immunostained with an anti-GM1 antibody (immunostaining of GM1 on the plasma membrane  
is indicated by arrows). 
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C. Cells were transfected with siRNAs as in panel A for 48 hours. Live cells were stained directly 
with anti-ASM antibodies at room temperature for 1 hour. Cells were then fixed, and processed for 
staining with by secondary antibodies and imaging. 
D. Extracellular recombinant ASM enzyme can rescue the trafficking defects of SNAP23 in the 
ASM siRNA-treated cells. U373-MG cells were transfected with 50 nM control and ASM siRNAs 
for 48 hours.  In one set of the ASM siRNA-treated cells (right panel), purified recombinant  
active recombinant human ASM enzyme (4 μg/ml final) was added to the culture media for 2 
hours.  Cells were then fixed, processed by immunostaining with anti-SNAP23 antibody, and 
examined by fluorescence microscopy.  
E. For quantification, the relative abundance of SNAP23 under all three conditions in panel C was 
measured (200 cells from each condition), as in Fig. 3C, and then normalized to control cells. 
Three independent experiments were measured to obtain the average (the mean value)  
of SNAP23 distribution on the plasma membrane (statistical significant, P<0.01, Student’s t-test). 
F. A model for the ASM function in regulation of SNAP23 and Lyn trafficking. ASM acts at the 
outer-leaflet of the plasma membrane (PM) to convert sphingomyelins (SM) to ceramides (CER). 
While CER are found in both leaflets of the plasma membrane, SM are mainly on the outer leaflet 
of the plasma membrane. Ceramides can retrogradely traffic back to Golgi (TGN).  
On the Golgi membrane, ceramides recruit the palmitoylated proteins such as SNAP23 and Lyn to 
facilitate the transport of these proteins out of the Golgi. SNAP23 and Lyn are carried by the 
ceramide-rich transport vesicles (possibly endosomes) en route to the plasma membrane, which 
eventually fused with the plasma membrane. On the plasma membrane, SNAP23 and Lyn  
are also associated with ceramides-rich lipid microdomains. When SNAP23 and Lyn are 
depalmitoylated, the depalmitoylated proteins become cytosolic, and then associate with Golgi to 
be palmitoylated again, starting another cycle of trafficking. When ASM is inactivated, SNAP23 
and Lyn are trapped in the Golgi, due to the lack of the ceramides on the Golgi membrane, which  
are essential for the transport of the palmitoylated proteins out of the Golgi.  
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Table S1. The spectral counting data for the protein hits that are decreased in the DRM 
association following ASM siRNA treatment. 
U373-MG cells were treated with the luciferase siRNAs (siLuc) as control or with ASM specific siRNAs 
(siASM). DRM fractions from both samples were processed and analyzed by OrbiTrap mass-spectrometer. 
Proteomic data were analyzed by Proteome Discoverer software and Scaffold software. The filtered spectra 
counts were quantitated according to (Liu et al., 2004; Old et al., 2005) to derive the RSC, which is the log2 
ratio of abundance between Samples 1 and 2. The RSC score was then used to calculate the ratio of 
abundance between Samples 1 (siLuc) and 2 (siASM). Fold of protein abundance change between control 
siLuc and siASM, as well as numbers of the peptides identified in each condition, are listed in the middle 
columns. The high confidence group are consisted of proteins each identified by at least two unique peptides, 
and the ratio of abudundance change >2. The low confidence group are consisted of proteins each identified 
by at least one unique peptides, and the ratio of abudance change >1.8. 
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siLuc siASM siLuc/siASM
Bio,View:Identified,Proteins,(878) Accession,Number #,peptides #,peptides Fold of Change
High%Confidence,%number%of%unique%peptides%number%>2,%fold%of%change%>2.0,%from%siLuc/siASM%comparison
CD59,glycoprotein,,T,cell,activation IPI00011302 44 0 36.2
Putative,uncharacterized,protein,ZNF326 IPI00337602,(+1) 71 1 32.1
VAMP3,,VesicleXassociated,membrane,protein,3 IPI00549343 37 0 30.6
VesicleXtrafficking,protein,SEC22b IPI00006865 28 0 23.4
BetaX2Xmicroglobulin IPI00004656,(+1) 19 0 16.2
Caveolin,,scaffolding,protein,within,caveolar,membranes IPI00009236 63 4 12.2
5'Xnucleotidase,ecto,,CD73 IPI00009456 14 0 12.2
ATP,synthase,subunit,alpha,,mitochondrial IPI00440493 13 0 11.4
RPN2,,subunit,of,NXoligosaccharyl,transferase,complex IPI00028635,(+1) 12 0 10.6
VAMP7,,,vesicleXassociated,membrane,protein,7,,Isoform,1 IPI00020887 10 0 9
60,kDa,heat,shock,protein,,mitochondrial IPI00784154 8 0 7.4
RasXrelated,protein,RabX7a IPI00016342 7 0 6.6
Src family tyrosine kinase Yes IPI00013981 7 0 6.6
SyntaxinX16,,Isoform,B IPI00023149,(+1) 7 0 6.6
RPN1,,subunit,of,NXoligosaccharyl,transferase,complex IPI00025874 7 0 6.6
GlypicanX4 IPI00232571 20 2 6.5
CD90,,possible,cellXcell,or,cellXligand,interaction,ThyX1,membrane,glycoprotein IPI00022892,(+1) 18 2 5.9
Major,prion,protein,,Isoform,1 IPI00022284,(+4) 12 1 5.9
RasXrelated,protein,RabX1A,,isoform,1 IPI00005719,(+1) 6 0 5.8
GCP16,,palmitoyltransferase,,protein,palmitoylation IPI00480022,(+1) 6 0 5.8
Putative,receptor,for,complement,component,1,Q,,mitochondrial IPI00014230 6 0 5.8
Annexin,A2,,Isoform,2 IPI00418169,(+1) 16 2 5.3
TXcomplex,protein,1,subunit,beta IPI00297779 5 0 5
Ragulator,complex,protein,LAMTOR1,,mTOR,regulation IPI00016670 5 0 5
RasXrelated,protein,RXRas IPI00020418 5 0 5
MyeloidXassociated,differentiation,marker IPI00102685,(+1) 5 0 5
Serine/threonineXprotein,kinase,Nek2,,Isoform,1 IPI00021331 20 3 5
Cytochrome,c,oxidase,subunit,5A,,mitochondria, IPI00025086 5 0 5
RasXrelated,protein,RalXB IPI00004397 5 0 5
Erythrocyte,band,7,integral,membrane,protein IPI00219682 18 3 4.5
RasXrelated,protein,RabX5C IPI00016339 4 0 4.2
Proteolipid,protein,2,,function,unknown IPI00030362 4 0 4.2
Protein,FAM3C IPI00334282 4 0 4.2
SodiumXdependent,amino,acids,transporter IPI00019472 4 0 4.2
Limbic,systemXassociated,membrane,protein IPI00013303 4 0 4.2
SNAP23,,SynaptosomalXassociated,protein,23 IPI00010438 4 0 4.2
Pyruvate,kinase,PKM,,glycolysis IPI00479186 4 0 4.2
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GTPase,IMAP,family,member,8 IPI00168482 4 0 4.2
Cytochrome,bXc1,complex,subunit,Rieske,,mitochondrial IPI00026964 4 0 4.2
ATP,synthase,subunit,delta,,mitochondrial IPI00024920 4 0 4.2
91,kDa,protein IPI00871370,(+1) 4 0 4.2
Heat,shock,cognate,71,kDa,protein,iIsoform,1 IPI00003865 15 3 3.8
Peroxidasin,homolog,,isoform,1 IPI00016112 26 6 3.8
Secretory,carrierXassociated,membrane,protein,1,,Isoform,1 IPI00005129 10 2 3.5
Transmembrane,emp24,domainXcontaining,protein,10 IPI00028055 3 0 3.4
TXcomplex,protein,1,subunit,eta IPI00018465,(+3) 3 0 3.4
SynaptogyrinX2 IPI00013946,(+2) 3 0 3.4
StressX70,protein,,mitochondrial IPI00007765 3 0 3.4
RasXrelated,protein,RapX2b IPI00018364 3 0 3.4
RasXrelated,protein,RalXA IPI00217519 3 0 3.4
Protein,FAM162A IPI00023001,(+1) 3 0 3.4
Protein,disulfideXisomerase,PDI,,protein,folding IPI00010796 3 0 3.4
MitogenXactivated,protein,kinase,scaffold,protein,1 IPI00030919 3 0 3.4
ReticulonX3,,isoform,2 IPI00398795,(+3) 3 0 3.4
CD97,antigen,,Isoform,2,,potential,cell,adhesion,receptor IPI00299412,(+4) 3 0 3.4
IFM3,,InterferonXinduced,transmembrane,protein,3 IPI00303726 3 0 3.4
DeoxyribonucleaseX1Xlike,1 IPI00026125,(+1) 3 0 3.4
Cytochrome,c,oxidase,subunit,6B1 IPI00216085,(+1) 3 0 3.4
Cytochrome,c,oxidase,subunit,4,isoform,1,,mitochondrial IPI00006579 3 0 3.4
CofilinX1,,actin,cytoskeleton,regulation IPI00012011 3 0 3.4
CholineXphosphate,cytidylyltransferase,A IPI00329338,(+1) 3 0 3.4
cDNA,FLJ59191,,highly,similar,to,NADH,dehydrogenase,(ubiquinone),1,alpha,subcomplex,subunit,13 IPI00942935 3 0 3.4
TXcomplex,protein,1,subunit,theta, IPI00302925,(+1) 3 0 3.4
SyntaxinX10,,isoform,1 IPI00293402,(+1) 6 1 3.2
Prohibitin IPI00017334 8 2 2.8
Transporter,for,monocarboxylate,,metabolism IPI00024650 8 2 2.8
Cell,sruface,receptor,,cellXmatrix,interaction IPI00297160,(+19) 22 7 2.8
Ga(i)2,,isoform,1,,heterotrimeric,G,protein,subunit,,isoform,1 IPI00748145 5 1 2.8
Collapsin,response,mediator,protein,4,long,variant IPI00029111 23 8 2.6
TXcomplex,protein,1,subunit,delta IPI00302927,(+2) 2 0 2.6
StomatinXlike,protein,2 IPI00334190 2 0 2.6
RasXrelated,protein,RabX2A IPI00031169 2 0 2.6
RasXrelated,protein,RabX14 IPI00291928 2 0 2.6
Subunit,of,succinate,dehydrogenase,complex,,mitochondrial IPI00965327 2 0 2.6
Putative,chloride,channel,protein,7 IPI00020524,(+2) 2 0 2.6
Protein,disulfideXisomerase,A3 IPI00025252 2 0 2.6
ProfilinX1 IPI00216691 2 0 2.6
PeptidylXprolyl,cisXtrans,isomerase,A,,protein,folding IPI00419585 2 0 2.6
monocarboxylate,transporter,8 IPI00000655 2 0 2.6
MHC,class,I,antigen IPI00794678,(+2) 2 0 2.6
Lysosomal,acid,phosphatase IPI00003807 2 0 2.6
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Src,familty,tyrosine,kinase,Fyn,,isoform,3 IPI00166845,(+2) 2 0 2.6
,VesicleXassociated,membrane,proteinXassociated,protein,B/C,,isoform,1 IPI00006211 2 0 2.6
Uncharacterized,protein,C4orf52,,isoform,1 IPI00397994,(+1) 2 0 2.6
Solute,carrier,family,12,member,2,,isoform,1 IPI00022649,(+1) 2 0 2.6
RasXrelated,protein,RabX6A,,Isoform,1 IPI00023526,(+1) 2 0 2.6
Ovarian,carcinoma,immunoreactive,antigenXlike,protein IPI00555902 2 0 2.6
MitogenXactivated,proteinXbinding,proteinXinteracting,protein,iIsoform,1 IPI00032409 2 0 2.6
GDNF,family,receptor,alphaX1,,isoform,1 IPI00008148,(+1) 2 0 2.6
Elongation,factor,1Xdelta,,isoform,1 IPI00023048,(+2) 2 0 2.6
Electron,transfer,flavoprotein,subunit,beta,,isoform,1 IPI00004902,(+1) 2 0 2.6
E3,ubiquitinXprotein,ligase,CHIP,,isoform,1 IPI00025156,(+1) 2 0 2.6
ApoptosisXinducing,factor,1,,Isoform,1,,mitochondrial IPI00000690,(+1) 2 0 2.6
Integral,membrane,protein,2B,,amyloid,precursor,processing IPI00031821 2 0 2.6
HippocalcinXlike,protein,1,,calcium,binding,and,sensing IPI00219344 2 0 2.6
Ga(i)3,,G(k),subunit,alpha,,heterotrimeric,G,protein,subunit IPI00220578 2 0 2.6
Guanine,nucleotideXbinding,protein,G(I)/G(S)/G(O),subunit,gammaX12 IPI00221232 2 0 2.6
MICOS,complex,subunit,MIC19,,mitochondrial IPI00015833,(+4) 2 0 2.6
CD81,,TetraspaninX28,,cell,surface,protein IPI00000190,(+1) 2 0 2.6
Calmodulin IPI00075248,(+3) 2 0 2.6
CalciumXbinding,mitochondrial,carrier,protein,Aralar2 IPI00007084,(+1) 2 0 2.6
BXcell,receptorXassociated,protein,31 IPI00218200,(+1) 2 0 2.6
ATP,synthase,subunit,b,,mitochondrial IPI00029133 2 0 2.6
Src,family,tyrosine,kinase,Lyn,,isoform,B IPI:IPI00432416.4 2 0 2.6
Annexin,A1 IPI00218918 2 0 2.6
Sortilin IPI00217882 7 2 2.5
Ephrin,typeXA,receptor,2,,receptor,tyrosine,kinase IPI00021267 4 1 2.3
Secretory,carrierXassociated,membrane,protein,3,,isoform,1 IPI00306382 18 8 2.1
Low Confidence, Number of unique peptides > 1, fold of change > 1.8, from siLuc/siASM comparison
SyntaxinX7,,isoform,1 IPI00289876,(+1) 11 5 1.96
Transmembrane,protein,C2orf18 IPI00550440,(+2) 5 2 1.9
DolichylXdiphosphooligosaccharideXXprotein,glycosyltransferase,48,kDa,subunit IPI00297084 5 2 1.9
VXtype,proton,ATPase,subunit,d,1 IPI00034159 3 1 1.9
Translation,initiation,factor,eIFX2B,subunit,epsilon IPI00011898,(+1) 3 1 1.9
ATP,synthase,subunit,gamma,,Isoform,liver,,mitochondrial IPI00478410 3 1 1.9
Seprase,,isoform,1 IPI00295461,(+1) 3 1 1.9
Hormonally,upXregulated,neu,tumorXassociated,kinase IPI00219553,(+1) 3 1 1.9
14X3X3,protein,gamma IPI00220642 3 1 1.9
Vesicle,transport,through,interaction,with,tXSNAREs,homolog,1A IPI00059472,(+1) 1 0 1.8
Vacuolar,protein,sortingXassociated,protein,45 IPI00090327 1 0 1.8
VXtype,proton,ATPase,subunit,B,,brain,isoform IPI00007812 1 0 1.8
VXtype,proton,ATPase,116,kDa,subunit,a,isoform,2 IPI00000425 1 0 1.8
tumor,protein,D54,isoform,a IPI00399265,(+4) 1 0 1.8
tropomyosin,alphaX3,chain,isoform,1 IPI00183968,(+7) 1 0 1.8
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Translocator,protein IPI00026850 1 0 1.8
TransgelinX2 IPI00550363,(+1) 1 0 1.8
TMEM181,protein,(Fragment) IPI00166790,(+1) 1 0 1.8
TXcomplex,protein,1,subunit,zeta IPI00027626 1 0 1.8
TXcomplex,protein,1,subunit,gamma,isoform,b IPI00290770,(+3) 1 0 1.8
Sodium/potassiumXtransporting,ATPase,subunit,betaX3 IPI00008167 1 0 1.8
SideroflexinX1 IPI00009368 1 0 1.8
Regulator,of,GXprotein,signaling,19 IPI00028108 1 0 1.8
RasXrelated,protein,RapX1b IPI00015148 1 0 1.8
RasXrelated,protein,RabX11B IPI00020436 1 0 1.8
ProlactinXinducible,protein IPI00022974 1 0 1.8
PodocalyxinXlike,protein,1,precursor IPI00299116,(+2) 1 0 1.8
PeptidylXprolyl,cisXtrans,isomerase,B IPI00646304 1 0 1.8
NADH,dehydrogenase,[ubiquinone],ironXsulfur,protein,8,,mitochondrial IPI00010845 1 0 1.8
NADH,dehydrogenase,[ubiquinone],flavoprotein,2,,mitochondrial IPI00291328,(+2) 1 0 1.8
NADH,dehydrogenase,[ubiquinone],1,beta,subcomplex,subunit,10 IPI00479905 1 0 1.8
NADH,dehydrogenase,[ubiquinone],1,alpha,subcomplex,subunit,5 IPI00554681 1 0 1.8
Mitochondrial,import,inner,membrane,translocase,subunit,Tim23 IPI00007309,(+5) 1 0 1.8
Matrix,metalloproteinaseX14 IPI00218398,(+1) 1 0 1.8
Vesicle,transport,through,interaction,with,tXSNAREs,homolog,1B,,isoform,Long IPI00063784 1 0 1.8
Protein,SON,,isoform,F IPI00000192,(+3) 1 0 1.8
Integrin,alphaX6,,isoform,AlphaX6X1X2B IPI00010697,(+6) 1 0 1.8
Zinc,finger,protein,781,,isoform,1 IPI00853563 1 0 1.8
VoltageXdependent,anionXselective,channel,protein,3,,isoform,1 IPI00031804,(+1) 1 0 1.8
Transmembrane,protein,87B,,isoform,1 IPI00783380,(+1) 1 0 1.8
Transmembrane,protein,55B,,isoform,1 IPI00030530,(+1) 1 0 1.8
TransX2,3XenoylXCoA,reductase,,isoform,1 IPI00100656 1 0 1.8
TBC,domainXcontaining,protein,kinaseXlike,protein,,isoform,1 IPI00291665 1 0 1.8
Secretory,carrierXassociated,membrane,protein,4,,isoform,1 IPI00056310,(+2) 1 0 1.8
Pyruvate,dehydrogenase,E1,component,subunit,beta,,isoform,1,,mitochondrial IPI00003925,(+2) 1 0 1.8
Putative,adenosylhomocysteinase,2,,isoform,1 IPI00182938,(+2) 1 0 1.8
Phosphatidylinositol,4Xkinase,alpha,,isoform,1 IPI00070943 1 0 1.8
Mitochondrial,Rho,GTPase,2,,isoform,1 IPI00465059 1 0 1.8
ExportinX2,,isoform,1 IPI00022744,(+1) 1 0 1.8
ErlinX2,,isoform,1 IPI00026942 1 0 1.8
CytoskeletonXassociated,protein,4,,isoform,1 IPI00141318,(+1) 1 0 1.8
Cell,cycle,control,protein,50A,,isoform,1 IPI00019381,(+2) 1 0 1.8
ATP,synthase,subunit,d,,,isoform,1,,mitochondrial IPI00220487 1 0 1.8
FAM73A,protein IPI00168047 1 0 1.8
Dystroglycan IPI00028911 1 0 1.8
Dihydrolipoyl,dehydrogenase,,mitochondrial IPI00015911 1 0 1.8
cytochrome,c,oxidase,subunit,VIIa,polypeptide,2,(liver),precursor IPI00026570,(+1) 1 0 1.8
Cytochrome,c,oxidase,subunit,6C IPI00015972 1 0 1.8
Cytochrome,c,oxidase,subunit,5B,,mitochondrial IPI00021785 1 0 1.8
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Cytochrome,c,oxidase,subunit,2 IPI00017510 1 0 1.8
cDNA,FLJ56280,,highly,similar,to,Endoplasmic,reticulumXGolgi,intermediate,compartment,protein,1 IPI00003635,(+1) 1 0 1.8
cDNA,FLJ56157,,highly,similar,to,Glucosylceramidase IPI00021807,(+2) 1 0 1.8
Calcyphosin IPI00792011,(+1) 1 0 1.8
ATP,synthase,subunit,O,,mitochondrial IPI00007611 1 0 1.8
ADP/ATP,translocase,1 IPI00022891 1 0 1.8
7Xdehydrocholesterol,reductase IPI00294501 1 0 1.8
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Table S2. The spectral counting data for the protein hits that are increased in the DRM 
association following ASM siRNA treatment. 
Experiments, data analyses and quantitation were conducted similar as in the legends of 
Supplementary Table 1. Shown are the proteins which show abundance change greater than >2-
fold between the sample 2 (siASM) and Samples 1 (siLuc). Fold of protein abundance change 
between siASM and control siLuc, as well as numbers of the peptides identified in each condition, 
are listed in the middle columns. 
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siLuc siASM siASM/siLuc
Bio	  View:Identified	  Proteins	  (878) Accession	  Number #	  peptides #	  peptides Fold	  of	  Change
High	  Confidence,	  number	  of	  unique	  peptides	  number	  >2,	  fold	  of	  change	  >2.0,	  from	  siASM/siLuc	  comparison
Myoferlin,	  isoform	  1 IPI00021048	  (+1) 1 101 45.4
Flotillin-­‐1 IPI00027438 1 86 38.8
Flotillin-­‐2 IPI00789008 1 61 27.7
Alpha-­‐enolase,	  isoform	  alpha IPI00465248 0 27 22.6
Moesin IPI00219365	  (+1) 0 24 20.2
Reticulon-­‐4,	  isoform	  2 IPI00298289 0 21 17.8
Golgi	  apparatus	  protein	  1,isoform	  2 IPI00414717	  (+2) 0 19 16.2
Mitochondrial	  inner	  membrane	  protein,	  isoform	  2 IPI00554469 0 17 14.6
Inositol	  1,4,5-­‐trisphosphate	  receptor	  type	  3 IPI00291607 0 14 12.2
Vesicle-­‐fusing	  ATPase IPI00006451	  (+1) 0 12 10.6
Cytochrome	  b-­‐c1	  complex	  subunit	  1,	  mitochondrial IPI00013847 2 31 9.9
NADH	  dehydrogenase	  [ubiquinone]	  iron-­‐sulfur	  protein	  2,	  mitochondrial IPI00025239	  (+1) 0 11 9.8
Apolipoprotein	  B-­‐100 IPI00022229 0 11 9.8
Trifunctional	  enzyme	  subunit	  beta,	  mitochondrial IPI00022793 0 10 9
Cathepsin	  D IPI00011229 0 10 9
Heat	  shock	  protein	  HSP	  90-­‐beta IPI00414676 0 9 8.2
Cytochrome	  b-­‐c1	  complex	  subunit	  2,	  mitochondrial IPI00305383 2 25 8.1
Metalloreductase	  STEAP3,	  isoform	  1 IPI00019350	  (+3) 0 8 7.4
Cation-­‐dependent	  mannose-­‐6-­‐phosphate	  receptor IPI00025049 0 7 6.6
Phosphoglycerate	  kinase	  1 IPI00169383 2 18 5.9
V-­‐type	  proton	  ATPase	  116	  kDa	  subunit	  a	  isoform	  1,	  isoform	  2 IPI00743576	  (+2) 2 18 5.9
DNA-­‐dependent	  protein	  kinase	  catalytic	  subunit,	  isoform	  1 IPI00296337 0 6 5.8
Carboxypeptidase	  D IPI00027078 3 22 5.5
Vimentin IPI00418471 0 5 5
Very	  low-­‐density	  lipoprotein	  receptor,	  isoform	  Long IPI00024273	  (+2) 2 15 5
Integrin	  beta-­‐4,	  Isoform	  Beta-­‐4C IPI00027422	  (+3) 0 5 5
Integrin	  beta-­‐3,	  Isoform	  Beta-­‐3A IPI00303283 0 5 5
Calcium-­‐transporting	  ATPase	  type	  2C	  member	  1,	  isoform	  2 IPI00220473	  (+8) 0 5 5
Surfeit	  locus	  protein	  4,	  isoform	  1 IPI00005737	  (+2) 0 5 5
Plexin-­‐D1,	  isoform	  1 IPI00412492	  (+1) 0 5 5
Epoxide	  hydrolase	  1 IPI00009896 0 5 5
Collagen	  alpha-­‐3(V)	  chain IPI00018279 0 5 5
Conserved	  hypothetical	  protein IPI00916096 7 38 4.8
Neuroblast	  differentiation-­‐associated	  protein	  AHNAK IPI00021812 1 9 4.6
LAMP-­‐2A	  of	  Lysosome-­‐associated	  membrane	  glycoprotein	  2 IPI00009030	  (+2) 1 9 4.6
Endoplasmin IPI00027230 1 9 4.6
Sulfide:quinone	  oxidoreductase,	  mitochondrial IPI00009634 0 4 4.2
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Protein	  disulfide-­‐isomerase	  A4 IPI00009904 0 4 4.2
Desmoglein-­‐4,	  isoform	  2 IPI00428691	  (+1) 0 4 4.2
Tenascin,	  isoform	  1 IPI00031008	  (+6) 0 4 4.2
Leucyl-­‐cystinyl	  aminopeptidase,	  isoform	  1 IPI00307017	  (+1) 0 4 4.2
Heterogeneous	  nuclear	  ribonucleoprotein	  M,	  isoform	  1 IPI00171903	  (+1) 0 4 4.2
Gelsolin,	  isoform	  1 IPI00026314	  (+2) 0 4 4.2
High	  affinity	  cationic	  amino	  acid	  transporter	  1 IPI00027728 0 4 4.2
Ceruloplasmin IPI00017601	  (+1) 0 4 4.2
Calpain-­‐1	  catalytic	  subunit IPI00011285 0 4 4.2
A-­‐kinase	  anchor	  protein	  6 IPI00297089 0 4 4.2
Niemann-­‐Pick	  C1	  protein IPI00005107 1 8 4.1
Translational	  activator	  GCN1 IPI00001159 1 7 3.7
signal-­‐regulatory	  protein	  alpha	  precursor IPI00332887	  (+1) 0 3 3.4
Serotransferrin IPI00022463 0 3 3.4
Prostaglandin	  F2	  receptor	  negative	  regulator IPI00022048 0 3 3.4
Prolow-­‐density	  lipoprotein	  receptor-­‐related	  protein	  1 IPI00020557 0 3 3.4
NudC	  domain-­‐containing	  protein	  2 IPI00103142 0 3 3.4
TGN51	  of	  Trans-­‐Golgi	  network	  integral	  membrane	  protein	  2 IPI00012545	  (+4) 0 3 3.4
Gnas-­‐2	  of	  Guanine	  nucleotide-­‐binding	  protein	  G(s)	  subuni,	  	  alpha	  isoforms	  short IPI00219835	  (+1) 0 3 3.4
Perilipin-­‐3,	  isoform	  B IPI00303882 0 3 3.4
Adenylate	  kinase	  domain-­‐containing	  protein	  1,	  isoform	  6 IPI00552962	  (+1) 0 3 3.4
Protein	  disulfide-­‐isomerase	  A6,	  isoform	  2 IPI00299571	  (+1) 0 3 3.4
Sodium/potassium-­‐transporting	  ATPase	  subunit	  beta-­‐1,	  isoform	  1 IPI00747849	  (+1) 0 3 3.4
Heparan	  sulfate	  2-­‐O-­‐sulfotransferase	  1,	  isoform	  1 IPI00549891 0 3 3.4
Choline	  transporter-­‐like	  protein	  2,	  isoform	  1 IPI00549521 0 3 3.4
CD276	  antigen,	  isoform	  1 IPI00410488	  (+3) 0 3 3.4
Catenin	  beta-­‐1,	  isoform	  1 IPI00017292	  (+1) 0 3 3.4
Calcium-­‐binding	  mitochondrial	  carrier	  protein	  SCaMC-­‐1,	  isoform	  1 IPI00337494 0 3 3.4
Integrin	  alpha-­‐2 IPI00013744 0 3 3.4
HCG1990625,	  isoform	  CRA_a IPI00969623 0 3 3.4
cDNA	  FLJ56903,	  highly	  similar	  to	  Tubulin	  beta-­‐7	  chain IPI00909140 0 3 3.4
cDNA	  FLJ56389,	  highly	  similar	  to	  Elongation	  factor	  1-­‐gamma IPI00000875	  (+1) 0 3 3.4
cDNA	  FLJ55574,	  highly	  similar	  to	  Calnexin IPI00020984	  (+1) 8 30 3.4
Transferrin	  receptor	  protein	  1 IPI00022462 21 73 3.3
NADH-­‐ubiquinone	  oxidoreductase	  75	  kDa	  subunit IPI00604664	  (+1) 1 6 3.2
C-­‐type	  mannose	  receptor	  2 IPI00005707 1 6 3.2
Transmembrane	  protein	  87A,	  isoform	  1 IPI00783698	  (+1) 3 11 2.9
Voltage-­‐dependent	  anion-­‐selective	  channel	  protein	  2,	  isoform	  2 IPI00024145	  (+4) 2 8 2.8
DnaJ	  homolog	  subfamily	  C	  member	  13 IPI00307259 1 5 2.8
Protein	  S100-­‐A9 IPI00027462	  (+1) 0 2 2.6
proteasome-­‐associated	  protein	  ECM29	  homolog IPI00157790 0 2 2.6
N-­‐acetylglucosamine-­‐6-­‐sulfatase IPI00012102	  (+1) 0 2 2.6
Leucine-­‐rich	  PPR	  motif-­‐containing	  protein,	  mitochondrial IPI00783271 0 2 2.6
Neurofascin,	  Isoform	  7 IPI00384998	  (+11) 0 2 2.6
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nhibitor	  of	  nuclear	  factor	  kappa-­‐B	  kinase-­‐interacting	  protein,	  isoform	  4 IPI00043598 0 2 2.6
Inositol	  1,4,5-­‐trisphosphate	  receptor	  type	  1,	  isoform	  3 IPI00218659	  (+4) 0 2 2.6
Semaphorin-­‐4B,	  isoform	  2 IPI00513964 0 2 2.6
Multidrug	  resistance-­‐associated	  protein	  1,	  isoform	  2 IPI00008338	  (+6) 0 2 2.6
Dynein	  heavy	  chain	  2,	  axonemal,	  isoform	  2 IPI00651691	  (+1) 5 15 2.6
Titin,	  isoform IPI00759754	  (+4) 0 2 2.6
Putative	  SMEK	  homolog	  3,	  isoform	  1 IPI00900377 0 2 2.6
Nicastrin,	  isoform	  1 IPI00021983	  (+1) 0 2 2.6
NADH	  dehydrogenase	  [ubiquinone]	  flavoprotein	  1,	  mitochondrial,	  isoform	  1 IPI00028520	  (+1) 0 2 2.6
Kinectin,	  isoform	  1 IPI00328753 0 2 2.6
Glial	  fibrillary	  acidic	  protein,	  isoform	  1 IPI00025363	  (+2) 0 2 2.6
Epidermal	  growth	  factor	  receptor,	  isoform	  1 IPI00018274 0 2 2.6
Inositol	  monophosphatase	  3 IPI00787853 0 2 2.6
HLA	  class	  I	  histocompatibility	  antigen,	  alpha	  chain	  G IPI00015988	  (+3) 0 2 2.6
Histone	  H3.2 IPI00171611	  (+6) 0 2 2.6
Fatty	  acid-­‐binding	  protein,	  epidermal IPI00007797 0 2 2.6
Ezrin IPI00843975	  (+1) 0 2 2.6
Dynein	  heavy	  chain	  domain-­‐containing	  protein	  1 IPI00936051 0 2 2.6
cDNA	  FLJ60299,	  highly	  similar	  to	  Rab	  GDP	  dissociation	  inhibitor	  beta IPI00031461	  (+1) 0 2 2.6
Alpha-­‐mannosidase	  2 IPI00003802 0 2 2.6
60S	  ribosomal	  protein	  L4 IPI00003918 0 2 2.6
Transmembrane	  9	  superfamily	  member	  4 IPI00021985	  (+1) 2 7 2.5
NADPH-­‐-­‐cytochrome	  P450	  reductase IPI00470467	  (+3) 1 4 2.3
NADH-­‐cytochrome	  b5	  reductase	  1 IPI00470674 1 4 2.3
Neuroplastin,	  isoform	  1 IPI00011578	  (+4) 1 4 2.3
CD166	  antigen,	  isoform	  1 IPI00015102	  (+3) 1 4 2.3
Acylglycerol	  kinase,	  isoform	  1,	  mitochondrial IPI00019353	  (+1) 1 4 2.3
cDNA	  FLJ52398,	  highly	  similar	  to	  Cadherin-­‐13 IPI00024046 1 4 2.3
Voltage-­‐dependent	  anion-­‐selective	  channel	  protein	  1 IPI00216308 8 20 2.3
Trifunctional	  enzyme	  subunit	  alpha,	  mitochondrial IPI00031522 2 6 2.2
Monocarboxylate	  transporter	  4 IPI00006666 2 6 2.2
Inner	  centromere	  protein,	  isoform	  2 IPI00759472	  (+1) 2 6 2.2
51	  kDa	  protein IPI00328883	  (+8) 2 6 2.2
HLA	  class	  I	  histocompatibility	  antigen,	  A-­‐2	  alpha	  chain IPI00876963	  (+3) 10 23 2.2
Lysosome	  membrane	  protein	  2 IPI00217766 6 14 2.1
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Table S3. List of proteins identified in ASM-sensitive DRM proteome that are also known to 
be palmitoylated proteins. 
Hits listed in supplementary Table 1 were cross-referenced to the palmitoyl-proteome database 
(SwissPalm) (Blanc et al., 2015), 65 proteins are found to be known as palmitoylated protein and 
listed here. Semi-quantitative mass-spectrometry data, including the fold of protein abundance 
change between cells treated with Luciferase siRNA (siLuc) and ASM siRNA (siASM), as well as 
the numbers of the peptides identified in each condition for each protein, are shown in the middle 
columns. The numbers of articles that reported the particular protein found in the palmitoyl-
proteomes is indicated in the second to the last column. Both UniProt accession number and IPI 
accession numbers are listed. Proteins are grouped according to their functional categories. 
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UniProt Protein,,name Protein,Functions,or,Biological,Process Fold siLuc siASM #,of,,articles IPI,database
accession,number of change peptides peptides palmitoy9proteome,studies Accession,Number
High%Confidence,%number%of%unique%peptides%number%>2,%fold%of%change%>2.0
Receptors,%Cell%surface%proteins%or%transporters:%
P13987 CD59 CD59*glycoprotein,*T*cell*activation 36.2 44 0 3*of*15 IPI00011302
P21589 NT5E 5'Dnucleotidase*ecto,*CD73 12.2 14 0 2*of*15 IPI00009456
P04216 THY1 CD90,*possible*cellDcell*or*cellDligand*interaction 5.9 18 2 2*of*15 IPI00022892*(+1)
Q07021 C1QBP Putative*receptor*for*complement*component*1*Q 5.8 6 0 6*of*15 IPI00014230
Q15758 SLC1A5 SodiumDdependent*amino*acids*transporter 4.2 4 0 10*of*15 IPI00019472
P48960 CD97 CD97*antigen,*isoform*2,*potential*cell*adhesion*receptor 3.4 3 0 1*of*15 IPI00299412*(+4)
P16070 CD44 CD44,*Cell*sruface*receptor,*cellDmatrix*interaction 2.8 22 7 8*of*15 IPI00297160*(+19)
P60033 CD81 CD81,*TetraspaninD28,*cell*surface*protein 2.6 2 0 8*of*15 IPI00000190*(+1)
P29317 EPHA2,*ECK Ephrin*typeDA*receptor*2,*receptor*tyrosine*kinase 2.3 4 1 1*of*15 IPI00021267
GTPases;%Other%Signaling%Proteins:%
P07947 YES Src family tyrosine kinase Yes 6.6 7 0 6*of*15 IPI00013981
P11234 RALB RasDrelated*protein*RalDB 5 5 0 5**of*15 IPI00004397
P10301 RRAS RasDrelated*protein*RDRas 5 5 0 9*of*15 IPI00020418
P11233 RALA RasDrelated*protein*RalDA 3.4 3 0 6*of*15 IPI00217519
P61226 Rap2b RasDrelated*protein*RapD2b 3.4 3 0 6*of*10 IPI00018364
P04899 GNAI2 Ga(i)2,*isoform*1,*heterotrimeric*G*protein*subunit 2.8 5 1 11*of*15 IPI00748145
P06241 FYN Src*familty*tyrosine*kinase*Fyn,*isoform*3 2.6 2 0 6*of*15 IPI00166845*(+2)
P08754 GNAI3 Ga(i)3,*G(k)*subunit*alpha,*heterotrimeric*G*protein*subunit 2.6 2 0 11*of*15 IPI00220578
P07948 LYN Src*family*tyrosine*kinase*Lyn,*isoform*B 2.6 2 0 3 of 15 IPI00432416*(+4)
Vesicular%Trafficking:%
Q15836 VAMP3 VAMP3,*VesicleDassociated*membrane*protein*3 30.6 37 0 11*of*15 IPI00549343
O75396 SEC22B VesicleDtrafficking*protein*Sec22B 23.4 28 0 3*of*15 IPI00006865
P51809 VAMP7 VAMP7,*VesicleDassociated*membrane*protein*7,*isoform*1 9 10 0 8*of*15 IPI00020887
P51149 RAB7 RasDrelated*protein*RabD7a 6.6 7 0 4*of*15 IPI00016342
O14662 STX16 SyntaxinD16,*Isoform*B 6.6 7 0 1*of*15 IPI00023149*(+1)
P62820 RAB1A RasDrelated*protein*RabD1A,*isoform*1 5.8 6 0 5*of*15 IPI00005719*(+1)
P07355 ANXA2 Annexin*A2,*calcium/phospholipidDbinding*protein 5.8 6 0 6*of*15 IPI00418169*(+1)
O00161 SNAP23 SNAP23,*SynaptosomalDassociated*protein*23 4.2 4 0 13*of*15 IPI00010438
P51148 RAB5C RasDrelated*protein*RabD*5C 4.2 4 0 7*of*15 IPI00016339
O15126 SCAMP1 Secretory*carrierDassociated*membrane*protein*1 3.5 10 2 9*of*15 IPI00005129
P49755 TMP21 Transmembrane*protein*Tmp21 3.4 3 0 3*of*15 IPI00028055
O43760 SYNGR2 SynaptogyrinD2 3.4 3 0 2*of*15 IPI00013946*(+2)
O60499 STX10 Syntaxin*10 3.2 6 1 6*of*15 IPI00293402*(+1)
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P61106 RAB14 RasDrelated*protein*RabD14 2.6 2 0 5*of*15 IPI00291928
O95292 VAPB VesicleDassociated*membrane*proteinDassociated*protein*B/C 2.6 2 0 2*of*15 IPI00006211
P20340 RAB6A RasDrelated*protein*RabD*6A 2.6 2 0 2*of*15 IPI00023526*(+1)
P61019 RAB2A RasDrelated*protein*RabD2A 2.6 2 0 4*of*15 IPI00031169
Q99523 SORT1 Sortillin,*as*sorting*receptor*on*Golgi*compartment 2.5 7 2 5*of*15 IPI00217882
P04083 ANXA1 Annexin*A1,*calcium/phospholipidDbinding*protein 2.6 2 0 4*of*15 IPI00218918
O15400 STX7 SyntaxinD7,*isoform*1 2 11 5 7*of*15 IPI00289876*(+1)
Cytoskeletal%Proteins:%
P27105 BND7 Erythrocyte*band*7*integral*membrane*protein 4.5 18 3 10*of*15 IPI00219682
P23528 CFL1 CofilinD1,*actin*cytoskeleton*regulation 3.4 3 0 5*of*15 IPI00012011
Q01628 IFM3 InterferonDinduced*transmembrane*protein*3 3.4 3 0 7*of*15 IPI00303726
P07737 PFN1 ProfilinD1,*actin*cytoskeleton*regulation 2.6 2 0 5*of*15 IPI00216691
Scaffolding%Proteins%and%Protein%Folding:%
Q03135 CAV1 Caveolin,*scaffolding*protein*within*caveolar*membranes 12.2 63 4 4*of*15 IPI00009236
P07237 PDIA1 Protein*disulfideDisomerase*PDI,*protein*folding 3.4 3 0 4*of*15 IPI00010796
P50990 CCT8 TDcomplex*protein*1*subunit*theta* 3.4 3 0 5*of*15 IPI00302925*(+1)
P50991 CCT4 TDcomplex*protein*1*subunit*delta 2.6 2 0 4*of*15 IPI00302927*(+2)
P62937 PPIA PeptidylDprolyl*cisDtrans*isomerase*A,*protein*folding 2.6 2 0 7*of*15 IPI00419585
P30101 PDIA3 Protein*disulfideDisomerase*A3 2.6 2 0 3*of*15 IPI00025252
Q9Y287 ITM2B Integral*membrane*protein*2B,*amyloid*precursor*processing 2.6 2 0 7*of*15 IPI00031821
Metabolism:%
P04844 RPN2 RPN2,*Subunit*of*NDoligosaccharyl*transferase*complex 10.6 12 0 4*of*15 IPI00028635*(+1)
P04843 RPN1 RPN1,*Subunit*of*NDoligosaccharyl*transferase*complex 6.6 7 0 3*of*15 IPI00025874
P20674 COX5A Cytochrome*c*oxidase*subunit*5A,*mitochondria* 5 5 0 2*of*15 IPI00025086
P14618 PKM Pyruvate*kinase*PKM,*glycolysis 4.2 4 0 6*of*15 IPI00479186
P47985 UQCRFS1 Cytochrome*bDc1*complex*subunit*11,*mitochondrial 4.2 4 0 3*of*15 IPI00026964
P53985 SLC16A1 Transporter*for*monocarboxylate,*metabolism 2.8 8 2 2*of*15 IPI00024650
P31040 SDHA Subunit*of*Succinate*dehydrogenase*complex,*mitochondrial 2.6 2 0 3*of*15 IPI00965327
Q9NX63 CHCHD3 MICOS*complex*subunit*MIC19,*mitochondrial 2.6 2 0 5*of*15 IPI00015833*(+4)
Others
Q7Z5G4 GOLGA7 GCP16,*palmitoyltransferase,*protein*palmitoylation 5.8 6 0 9*of*15 IPI00480022*(+1)
Q6IAA8 LAMTOR1 Ragulator*complex*protein*LAMTOR1,*mTOR*regulation 5 5 0 11*of*15 IPI00016670
Q96S97 MYADM MyeloidDassociated*differentiation*marker 5 5 0 5*of*15 IPI00102685*(+1)
Q04941 PLP2,*A4 Proteolipid*protein*2,*function*unknown 4.2 4 0 5*of*15 IPI00030362
Q96A26 FAM162A Protein*FAM162A 3.4 3 0 5*of*15 IPI00023001*(+1)
O95831 AIFM1 ApoptosisDinducing*factor*1,*Isoform*1,*mitochondrial 2.6 2 0 2*of*15 IPI00000690*(+1)
P37235 HPCAL1 HippocalcinDlike*protein*1,*calcium*binding*and*sensing 2.6 2 0 2*of*15 IPI00219344
Q56VL3 OCIAD2 Ovarian*carcinoma*immunoreactive*antigenDlike*protein 2.6 2 0 1*of*15 IPI00555902
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